



Sri Devaraj Urs Academy of Higher Education & Research

Comprising Sri Devaraj Urs Medical College

(A Deemed to be University)

Research and Development Cell

Central Ethics Committee Re-registered under CDSCO -Registration No. ECR/425/Inst/KA/2013/RR-20 dated 28.4.2020

Metric 3.5.2

3.5.2.1: Total amount generated from consultancy during the last year

Sl.No.	Training/ Consultancy projects
	2024-25
1.	Clinical trials-3 in number
2.	National Scientific Conclave-2025
3.	Internship Program conducted by Dept. of Forensic medicine, SDUMC Kolar.
4.	Conference, Workshop and Internship Program conducted by Dept. of Physiotherapy, SDUAHER.
5.	Internship Program in Dept. of Cell Biology and Molecular Genetics, SDUAHER.
6.	One day CME on World Intellectual Property Rights day 2025
7.	Internship Program in Dept. Clinical Nutrition and Dietetics, SDUAHER
8.	One day CME on World Intellectual Property Rights day 2025
9.	NSS Camp conducted by Sri Devaraj Urs college of Nursing



Prof. Dr. Kalyani . R.
MD(Path), Ph.D, FAMS, FICP, FIAMS, FIMSA, FKSTA
Director
Research and Development Cell, SDUAHER
Professor & Former Head
Dept. of Pathology, SDUMC

Exhibit-B

PART 1- Budget & Payment Schedule

Protocol Title: A prospective, Randomized, Double Blind, Multicentric, Parallel Group Phase-III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of BP01 (Bevacizumab) Versus EU approved Avastin® along with chemotherapy XELOX in metastatic colorectal cancer patients.”

Protocol No: ICS/CUR/2023-006

Estimated Per Subject Fee: [including all fixed costs, institutional overheads (as applicable) & other Compensation below]; Based on the ongoing discussions with site team it has been assumed that the site and PI will make all possible attempt to achieve at least 3-4 enrolments per month in the study. Accordingly, the following study budget has been offered to proportionately compensate for the efforts and resources being utilized by the site and study team members.

VISITS	PI	Co-I	CRC/ Nurse	Phlebo	Pharmacist	Patient TA	Cardiologist	Day Care +Pre medication +Food Allowance	Total
Screening (V1)	5000	2000	1500	500	0	0	1500	0	10500
Randomization / Cycle 1 (V2)	5000	2000	1500	500	500	400	0	3000	12900
Cycle 2 (V3)	5000	2000	1500	500	500	400	0	3000	12900
Cycle 3 (V4)	5000	2000	1500	500	500	400	0	3000	12900
Cycle 4 (V5)	5000	2000	1500	500	500	400	1500	3000	14400
Cycle 5 (V6)	5000	2000	1500	500	500	400	0	3000	12900
Cycle 6 (V7)	5000	2000	1500	500	500	400	0	3000	12900
EOS / FU (V8)	5000	2000	1500	500	0	400	1500	0	10900
Sub Total	40000	16000	12000	4000	3000	2800	4500	18000	100300
IOH 25%	10000	4000	3000	1000	750	700	1125	4500	25075
Grand Total	50000	20000	15000	5000	3750	3500	5625	22500	125375


CRO Trial Site
Dr. D. Lakshmi R.
 Ph.D, FAMS, FICP, FIAMS, FIMSA, FKSTA
Director
 Research and Development Cell, SDUAHER
 Professor & Former Head
 Dept. of Pathology, SDUMC





Principal Investigator
Dr. D. Lakshmi R.
 Prof. of Medical Oncology
 KMC No. 24954
 Sri Devaraj Urs Medical College
 Tamaka, Kolar-563103.

PRICE LIST FOR RADIOLOGY/IMAGING TESTING

Test	Frequency	Total Cost
Bone Scan (Whole Body) (includes interpretation and report)	1	12000
Brain CT (includes interpretation and report)	1	2000
Chest CT (includes interpretation and report)	1	2500
Chest CT Contrast (includes interpretation and report)	1	3000
Whole Abdomen CT (includes interpretation and report)	3	9000
Whole Abdomen CT Contrast (includes interpretation and report)	3	15000
Brain MRI (includes interpretation and report)	1	3500
Chest MRI (includes interpretation and report)	1	4500
Whole Abdomen MRI (includes interpretation and report)	3	22500
12 Lead ECG	8	1600
MUGA /2DECHO	3	6000
Chest Xray	1	200


CRO Trial Site
Prof. Dr. Kalyani . R.
 MD(Pathn), Ph.D., FAMS, FICP, FIAMS, FIMSA, FKSTA
Director
 Research and Development Cell, SDUAHER
 Professor & Former Head
 Dept. of Pathology, SDUMC




Principal Investigator
Dr. D. Lokanatha
 Prof. of Medical Oncology
 KMC No. 24954
 Sri Devaraj Urs Medical College
 Tamaka, Kolar


PRICE LIST FOR LABORATORY TESTING

NABL LAB ONLY

S.NO.	TEST	FREQUENCY	TOTAL
1	Hematology	8	30345
2	LFT: Total Bilirubin,ALP,AST,ALT	8	
3	KFT: Creatinine, BUN,Albumin,Creatinine clearance	8	
4	Coagulation Profile -D-DIMER	8	
5	PT/INR,APTT	8	
6	RT-PCR	1	
7	Serum Electrolytes NA ⁺ ,K ⁺ ,CL ⁻	8	
8	Urinalysis:Appearance,Bilirubin,Blood,Colour, Epithelial Cells,Glucose, Ketones, Nitrite, pH,Protein,RBCs,WBCs,Urobilinogen,Specific Gravity,	8	
9	Spot UACR (Dipstick Method)	4	
10	HIV	1	
11	HCV	1	
12	HBsAg	1	
13	Pregnancy Test (Serum)	1	
14	Pregnancy Test (Urine)	7	


CRO Trial Site
Prof. Dr. Kalyani . R.
 MD(Path), FR.D, FAMS, FICP, FIAMS, FIMSA, FKSTA
Director
 Research and Development Cell, SDUAHER
 Professor & Former Head
 Dept. of Pathology, SDUMC




Principal Investigator
Dr. D. Lokanatha
 Prof. of Medical Oncology
 KMC No. 24954
 Sri Devaraj Urs Medical College
 Tamaka, Kolar-563103.

Schedule I – Protocol

Study Title: A randomized, open label, multi-center, two-treatment, two-period, two-sequence, fully replicate, cross-over, multiple dose, steady-state, bioequivalence study of Olaparib Tablets 150 mg (2*150 mg tablets) of Alembic Pharmaceuticals Limited, India with Lynparza® 150mg Filtabletten Olaparib (2*150 mg tablets) of AstraZeneca AB, SE-151 85 Södertälje, Schweden, in adult patients with carcinoma of the ovary, breast, prostate or adenocarcinoma of the pancreas under fasting condition.

Study Number: CO240007

Schedule II: Study Budget

Evaluation	Type of Visit	Screening Part 01	Stabilization Period (at least 15 days prior to randomization)	Screening Part 02 (Within 07 days prior to randomization)	Period 1								Period 2				End of study safety assessment	Total
					Day 1	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13	Day 14		
	Visit	1	2	3	4	5	6	7	8	9	10	11	12	13	14			
	Investigator	4000	4000	4000	4000	3500	4000	4000	4000	3500	3500	4000	3500	3500	4000	53500		
	Study Coordinator	2500	2500	2500	2500	2500	2500	2500	2500	2500	2500	2500	2500	2500	2500	35000		
	Study Nurse	300	300	300	300	300	300	300	300	300	300	300	300	300	300	4200		
	Phlebotomist	350	350	350	350	350									350	1750		
	Social worker / Research Assistant	500	500	500	500	500	500	500	500	500	500	500	500	500	500	7000		
	12 lead ECG	550		550											550	1650		
	Chest X-Ray	800														800		
	D-dimer	2000		2000											2000	6000		
	Hospitalization						6000	6000	6000				6000	6000		36000		
	Patient Reimbursement	1000	1000	1000	1000	1000	1000	1000	1000	1000	1000	1000	1000	1000	1000	14000		
Total Cost																159900		
Total Cost Per Completed Patient (Including Institutional Overhead)																39975		
Total Cost Per Completed Patient (Including Institutional Overhead)																199875		

Payment will be prorated based on number of Days/visits completed.

Hospitalization Cost includes medication & any other resources used during the IP administration and hospital stay from Day 5 to Day 7 (Period 1) and Day 12 to Day 14 (Period 2). GST is subjected to the submission of GST compliant invoice & copy of GST registration certificate.

D-dimer will be performed for patients with metastatic castration-resistant prostate cancer (mCRPC) at local laboratory.

Local Laboratory charges except D-dimer will be paid if used during the study. Local Lab should be NABL accredited Chest X-ray P.A view (postero-anterior view). If no thoracic imaging is performed within 06 months prior to screening

Archival Cost of **INR 2,00,000** /- will be paid at the time of site close out visit for archival of study documents for **25 years**. If needed archival facility can be arranged at third party as per sponsor requirement. Archival cost will be not applicable in the case of no enrollment at site.

Schedule III - Payee Details

Study Title : A randomized, open label, multi-center, two-treatment, two-period, two-sequence, fully replicate, cross-over, multiple dose, steady-state, bioequivalence study of Olaparib Tablets 150 mg (2*150 mg tablets) of Alembic Pharmaceuticals Limited, India with Lynparza® 150mg Filmtabletten Olaparib (2*150 mg tablets) of AstraZeneca AB, SE-151 85 Södertälje, Schweden, in adult patients with carcinoma of the ovary, breast, prostate or adenocarcinoma of the pancreas under fasting condition.

Protocol Number : CO240007

Investigator : Dr. Lokanatha D

Site Address : R.L, Jalappa Hospital and Research Centre, Sri Devaraj Urs Medical College, Tamaka, Kolar- 563103, Karnataka, India

Payment Details:

Payee Name	Sri Devaraj Urs Academy of Higher Education and Research
Payee Address	Tamaka, Kolar, Karnataka, India
Bank Name and Address	Kotak Mahindra Bank Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar
Cheque/Draft (in favor of)	Sri Devaraj Urs Academy of Higher Education and Research
Sort Code	-
Account Number	2849611362
PAN Card Number	AAATS5344P
GST Number	29AAATS5344P1ZT
IFSC Code	KKBK0008269
BIC	-
IBAN	-
Contact person for payments	Dr. Bhuvana K, Chief Co-ordinating Officer, Clinical Trial Centre, SDUAHER, Kolar. Email Address: bhuvanak@sduaher.ac.in Contact Number: +91 99003 83738



सत्यमेव जयते

INDIA NON JUDICIAL

Government of Karnataka

Rs. 500

e-Stamp

Certificate No. : IN-KA84823512852466W
Certificate Issued Date : 03-Dec-2024 04:29 PM
Account Reference : NONACC (FI)/ kagcs108/ SUGGAPPA LAYOUT/ KA-GN
Unique Doc. Reference : SUBIN-KAKAGCSL0809879871053824W
Purchased by : KOUSHIK GANGULY
Description of Document : Article 5(J) Agreement (in any other cases)
Property Description : CLINICAL TRIAL AGREEMENT
Consideration Price (Rs.) : 0
 (Zero)
First Party : KOUSHIK GANGULY
Second Party : Dr BHUMA VENGGAMMA RL JALAPPA HOSPITAL KOLAR
Stamp Duty Paid By : KOUSHIK GANGULY
Stamp Duty Amount(Rs.) : 500
 (Five Hundred only)

सत्यमेव जयते



Please write or type below this line

CLINICAL TRIAL AGREEMENT
ERGOMED – INVESTIGATOR/INSTITUTION

This AGREEMENT is put in effect on the Effective Date and is made between:

Neuraxpharm Pharmaceuticals S.L. with registered offices at Av. Barcelona, 69. 08970 Sant Joan Despi, Barcelona, Spain (hereinafter referred to as the “Sponsor”) represented by **ERGOMED** whose

Country specific_INDIA, effective_23May2024

Page 1 of 37

Statutory Alert:

1. The authenticity of this Stamp certificate should be verified at 'www.shcilestamp.com' or using e-Stamp Mobile App of Stock Holding. Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please Inform the Competent Authority.

ERGOMED

representative is duly authorized to sign this Agreement on behalf of Sponsor, under the Letter of Authorisation issued on 10 July 2024.

and

Ergomed Clinical Research Private Limited, with registered offices at Wing A, Level 4, Dynasty Business Park, Andheri-Kurla Road, Andheri (East) Mumbai– 400059, Maharashtra, INDIA; CIN: U73200MH2013PTC249804 (hereinafter referred to as “**ERGOMED**”).

and

R.L. Jalappa Hospital and Research Centre, Sri Devaraj Urs Medical College, with registered offices at Tamaka, Kolar, Karnataka 563103 (hereinafter referred to as the “**INSTITUTION**”) represented by **Dr. Kalyani R, Director, Research & Development Cell, SDUAHER** and **Dr Rajesh Venkataraman, Central Trial Monitoring Organization** with business address at **Adichunchanagiri Hospital, Adichunchanagiri University at B.G Nagara, Mandya, Karnataka -571 448**.

and

Dr. Bhuma Vengamma (name of the INVESTIGATOR), with business address at **R.L. Jalappa Hospital and Research Centre, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka 563103**, (hereinafter referred to as the **INVESTIGATOR**).

WHEREAS:

ERGOMED and the Sponsor entered into an agreement by which the Sponsor requested and ERGOMED accepted to organize and manage the conduct of the following clinical trial in the interest and for the benefit of the Sponsor: “**A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy**”, Protocol „**NXPLEVE/24/P3-6**”(hereinafter: “**the Clinical Trial**”);

and

ERGOMED and Sponsor wish to involve the INSTITUTION and INVESTIGATOR in the Clinical Trial in the role referred to herein and the INSTITUTION and INVESTIGATOR accept such involvement.

WHEREBY IT IS AGREED AS FOLLOWS:

Article 1

Definitions

1.1. For the purpose of this Agreement, the following expressions shall have the meanings attributed to them below:

“**Adverse Event**” Any untoward medical occurrence (including a symptom or disease or an abnormal laboratory finding) during treatment with an investigational

drug or a pharmaceutical product in a patient or a trial subject that does not necessarily have a relationship with the treatment being given.

- “Affiliate”** Any business entity which controls, is controlled by, or is under the common control with the Sponsor or ERGOMED. For the purposes of this definition, a business entity shall be deemed to control another business entity if it owns, directly or indirectly, in excess of 50% of the voting interest in such business entity or the power to direct the management of such business entity. For the avoidance of any doubt, Affiliate shall mean as well a subsidiary or representative and branch office in any country.
- “Agreement”** This agreement comprising its clauses, schedules and any appendices attached to it.
- “Case Report Form”** or **“CRF”** A printed, optical, or electronic document, prepared by the Sponsor and/or ERGOMED and completed by the INVESTIGATOR, designed to record all of the Protocol required information to be reported to the Sponsor on each Clinical Trial Subject.
- “Clinical Trial”** That portion of the clinical trial referred to and described in the Protocol, that is to be conducted, at the INSTITUTION, under the supervision and direction of INVESTIGATOR, pursuant to the Protocol and subject to the terms and conditions of this Agreement.
- “Clinical Trial Product”** Levetiracetam extended-release granules
- “Clinical Trial Subject”** A person Enrolled in the Clinical Trial who meets all of the inclusion criteria and none of the exclusion criteria set forth in the Protocol and has signed a valid IRB/EC approved Informed Consent Form.
- “Data Subject”** or **“Data Principal”** Any natural person whose Personal Data is processed in accordance with this Agreement and who is listed in Schedule III.
- “Enrolment”** Recruitment (invitation to potential participants in the Clinical Trial for screening), screening (examination of the potential participants in the Clinical Trial by INVESTIGATOR for the purpose of determining the eligibility as per Protocol criteria, and, if a potential participant in the Clinical Trial is eligible for participation, presentation and discussion of the Clinical Trial implications with the potential participants in the Clinical Trial and obtaining from the potential participant in the Clinical Trial an Informed Consent Form to participate in the Clinical Trial), and/or randomization (as defined in the GCP). Also to include “Enrol” as the verb or any other derivation of the term.
- “Informed Consent Form”** The form prepared by the Sponsor and/or ERGOMED in conformance with the Regulations (as hereinafter defined), in consultation with the Sponsor, ERGOMED, and the IRB/EC, approved by the IRB/EC and signed by all Clinical Trial Subjects before they begin to participate in the Clinical Trial.

- “INVESTIGATOR’s team”** Qualified staff, determined by INVESTIGATOR, who participates in Clinical Trial e.g. INSTITUTION’s employees and/or INSTITUTION’s and / or INVESTIGATOR’s contractors and/or consultants.
- “IRB/EC”** Institutional Review Board(s) or Ethical Committees organized in accordance with the Regulations.
- “Party”** ERGOMED, INSTITUTION or INVESTIGATOR and except where otherwise provided “Parties” shall mean all of them.
- “Protocol”** **“A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy”**, Protocol „NXPLEVE/24/P3-6” as amended from time to time by Sponsor and approved by the IRB/EC and the Regulatory Authority. The Protocol, as it may be amended from time to time in accordance with Regulations, is incorporated into this Agreement by this reference as Schedule I.
- “Recruitment Period”** January 2025 to June 2026, or such later date as may be directed by Sponsor and approved by the competent authorities.
- “Regulations”** All laws, rules, regulations and guidelines that apply to or govern the conduct of the multi-centre Clinical Trial and/or the Clinical Trial, including without limitation the applicable Drugs and Cosmetics Act, 1940; New Drugs and Clinical Trial Rules, 2023; Medical Device Rules, 2017; Indian Council for Medical Research Guidelines for Biomedical and Health Research Involving Human Participants, 2017; Good Clinical Practices Guidelines issued by the Central Drugs Standards Control Organisation; ICH guidelines (including E6: Good Clinical Practice: Consolidated Guideline, and the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CHMP/ICH/135/95; hereinafter: **“GCP”**), together with the requirements in Clinical Trial Directive 2001/20/EC (4 April 2001) and the related guidance, guidelines and directives), the most recent version of Standard BS EN ISO 14155, the World Medical Association Declaration of Helsinki entitled ‘Ethical Principles for Medical Research Involving Human Subjects’ (**“Helsinki Declaration”**), all relevant laws of the European Union if directly applicable or of direct effect, all Indian laws and all relevant regulations and ordinances and all relevant laws and regulations regarding data protection and privacy, especially the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 - General Data Protection Regulation or **“GDPR”**; Information Technology Act, 2000; Information Technology (Reasonable security practices and procedures and sensitive personal data or information) Rules, 2011; Digital Personal Data Protection Act, 2023 (**“DPDPA”**); (together **“Data Protection Laws”**); and anti-bribery and ethical business conduct, and the requirements of the applicable regulatory authorities and the ethics committee and the policies of the INSTITUTION, as any of the foregoing may be amended from time to time, including the Clinical Trial Regulation EU 536/2014.

“Regulatory Authority” Any federal or state regulatory authority or government official or authority including the Central Drugs Standard Control Organization.

“Serious Adverse Event” An untoward medical occurrence during the Clinical Trial resulting in death or permanent disability, or hospitalisation of the ClinicalTrialSubject where the Clinical Trial Subject is an outdoor patient or a healthy person, prolongation of hospitalisation where the Clinical Trial Subject is an indoor-patient, persistent or significant disability or incapacity, congenital anomaly, birth defector life-threatening event.

“Services” The services of research and other services to be performed by the INSTITUTION and INVESTIGATOR in accordance with the Protocol and under the terms of this Agreement in order to carry out the Clinical Trial.

“Timelines” The dates set out in Schedule II hereto as may be amended by agreement between the Parties.

Article 2

Rights and obligations of the Parties

- 2.1. Pursuant to the terms and conditions of this Agreement, INSTITUTION through the efforts of INVESTIGATOR agrees to conduct the Clinical Trial according to the Protocol. INSTITUTION and INVESTIGATOR agree to use their best endeavours to recruit approximately four (4) Clinical Trial Subjects to participate in the Clinical Trial according to the Protocol and in accordance with the Timelines.

INSTITUTION shall ensure that the INVESTIGATOR uses her best efforts to Enrol only Clinical Trial Subjects who satisfy the Enrolment criteria according to the Protocol and shall not knowingly Enrol any participants which in her best professional judgment do not adequately meet the criteria for Clinical Trial Subjects.

The Sponsor or ERGOMED may request INSTITUTION to stop Enrolment at any time and for any reason.

- 2.2. INSTITUTION and INVESTIGATOR agree to perform the work required under the Protocol and this Agreement and to conduct the Clinical Trial with reasonable care and skill and in accordance with the Protocol, this Agreement, agreed standard operating procedures (“SOPs”) and Regulations.

By signing the Agreement, INSTITUTION and INVESTIGATOR acknowledge that they have received and reviewed the full text of Protocol (as herein attached as Schedule I).

- 2.3. INSTITUTION and INVESTIGATOR shall protect the rights and welfare of Clinical Trial Subjects participating in the Clinical Trial in accordance with the Protocol.

- 2.4. The Parties shall obtain and maintain any and all licenses, permits, approvals required under the Regulations. Where the INVESTIGATOR obtains and maintains any licenses, permit, or approvals a copy of the same shall be provided to ERGOMED.

Specifically, INVESTIGATOR shall provide relevant information on the Clinical Trial and obtain a signed Informed Consent Form from each potential participant in the Clinical Trial (or his/her legal guardian, as appropriate) before initiating any Clinical Trial specific procedures.

Any proposed modifications to any Informed Consent Form must be approved by both the IRB/EC and ERGOMED or the Sponsor before being used for the Clinical Trial.

All original signed Informed Consent Forms shall be retained by the INVESTIGATOR and be available for the inspection by Sponsor, ERGOMED, their representatives and any agency or their designee.

- 2.5. ERGOMED shall submit to IRB/EC and the Regulatory Authority for the Clinical Trial approval.

INSTITUTION shall immediately notify ERGOMED and Sponsor if the IRB/EC approval of the Clinical Trial is suspended, terminated, or made subject to other sanctions by any government agency. INVESTIGATOR shall submit all required reports to the IRB/EC and obtain continuing review and approval by the IRB/EC as required by applicable Regulations.

- 2.6. INSTITUTION and INVESTIGATOR each represent and warrant that the INVESTIGATOR has the necessary expertise to perform the Clinical Trial, and that INVESTIGATOR meets and shall continue to meet the conditions set out in the applicable Regulations, especially in the GCP.

INVESTIGATOR further represents that INVESTIGATOR's medical license is in good standing; that INVESTIGATOR has never had a medical license suspended or revoked or otherwise restricted; that INVESTIGATOR has never been disqualified or otherwise been restricted in conducting clinical studies by any regulatory authorities and that INVESTIGATOR is not currently the subject of any disciplinary actions by any state or federal agency.

- 2.7. The INSTITUTION and INVESTIGATOR represent and warrant that the Clinical Trial shall be conducted in accordance with Protocol approved by the IRB and the Regulatory Authority.

The Sponsor or ERGOMED may request the Protocol to be amended from time to time. The INSTITUTION and INVESTIGATOR may apply for an amendment to the Protocol to the IRB and the Regulatory Authority.

Notwithstanding the foregoing, in case of any administrative or logistic changes or minor amendments to the Protocol or deviations from the Protocol to eliminate immediate hazard to the Clinical Trial Subject, the INSTITUTION shall notify the IRB and Regulatory Authority in writing of administrative or logistic changes or minor amendments within 30 (thirty) days.

If an amendment to the Protocol is initiated by the INSTITUTION or INVESTIGATOR, approval from ERGOMED and/or the Sponsor shall be obtained in writing prior to notifying the IRB and the Regulatory Authority.

- 2.8. INSTITUTION and INVESTIGATOR shall arrange for any other relevant personnel required to carry out the Protocol and shall ensure that at all times during the Clinical Trial there is enough personnel to support the Clinical Trial. In addition to the Article 2.11., the

INSTITUTION and / or the INVESTIGATOR shall inform ERGOMED of any change in the INVESTIGATOR's team. The INSTITUTION and INVESTIGATOR shall be solely responsible for such personnel and Sponsor and ERGOMED shall not be responsible or liable for the personnel appointed by the INSTITUTION and INVESTIGATOR and such personnel shall at no point in time be construed as employees of the Sponsor and ERGOMED.

- 2.8.1. The INSTITUTION shall comply with all applicable employment and occupational health and safety laws and regulations, including those related to employment practices, wages, and worker classification (such as meal and rest break laws, wage notices, separation pay, and overtime laws) including but not limited to Minimum Wages Act, 1948; Contract Labour (Regulation & Abolition) Act, 1970; Workmen's Compensation Act, 1923; Employees' Provident Funds and Miscellaneous Provisions Act, 1952 as may be amended and replaced from time to time.
- 2.9. INSTITUTION represents and warrants that it possesses all facilities, personnel and resources necessary to properly conduct the Clinical Trial; that any laboratory work performed at INSTITUTION shall be performed at a laboratory that is certified under the applicable Regulations; and that INVESTIGATOR's team is qualified and has the training necessary to comply with the Protocol and applicable Regulations as well as the appropriate time to deliver the Services under this Agreement.
- 2.10. ERGOMED may, at its sole option, arrange for the availability of a study coordinator, duly qualified by training and / or experience, to manage the administrative functions at the Clinical Trial site.
- 2.11. INSTITUTION and INVESTIGATOR shall perform the Clinical Trial efficiently and within the Timelines set out in Schedule II and the Protocol. INSTITUTION and INVESTIGATOR acknowledge and agree that when rendering the Services time is of the essence. INVESTIGATOR shall give written notice to ERGOMED as soon as a delay in the Timelines can be anticipated.
- 2.12. INVESTIGATOR shall personally conduct the Clinical Trial and supervise the work of the INVESTIGATOR's team. INVESTIGATOR and INSTITUTION shall not delegate their obligations from this Agreement to any third party without the prior written approval of ERGOMED and competent authorities, where required. INVESTIGATOR and INSTITUTION shall be responsible for supervising any third party to whom they delegate Clinical Trial related duties and shall remain at all times fully and solely liable to ERGOMED for any performance undertaken by such third party.
- 2.13. ERGOMED has the right to replace INVESTIGATOR if there is information available to ERGOMED that the INVESTIGATOR does not perform her obligations as set out in this Agreement.
- 2.14. If the INVESTIGATOR and / or the INSTITUTION respectively retains the services of any third party to perform Clinical Trial related duties and functions, INVESTIGATOR and / or the INSTITUTION respectively should: (i) inform ERGOMED thereabout; (ii) ensure this third party is qualified to perform those Clinical Trial related duties and functions, as per Regulations; (iii) implement procedures to ensure integrity of such performed Clinical Trial related duties and functions and any data generated and (iv) remain at all times fully and solely liable to ERGOMED and the Sponsor for any performance undertaken by any such third parties for the quality, completeness and fulfilment of the work.

- 2.15. INVESTIGATOR shall timely prepare and maintain adequate and accurate case histories of each Clinical Trial Subject Enrolled in the Clinical Trial, recording all observations and other data pertinent to the Clinical Trial.

INVESTIGATOR shall collect clinical data related to the Clinical Trial in accordance with Regulations in a timely and organized manner that shall allow ERGOMED a complete and thorough analysis of the clinical findings of the Clinical Trial. INVESTIGATOR shall review and sign the forms used for data collection in a timely manner, including Case Report Forms.

INVESTIGATOR shall follow Clinical Trial Subjects in accordance with the Protocol, and INVESTIGATOR shall actively seek to contact Clinical Trial Subjects who discontinue and do not complete all necessary Protocol requirements. Upon completion of the Clinical Trial (whether prematurely or otherwise) INVESTIGATOR shall co-operate with Sponsor and ERGOMED in producing a report of the Clinical Trial detailing the methodology and results and containing an analysis of the results and drawing appropriate conclusions.

- 2.16. INSTITUTION shall ensure that INVESTIGATOR fully complies with adverse event provisions of the Protocol. The INVESTIGATOR and the INSTITUTION shall promptly ensure that adequate medical care is provided to the injured Clinical Trial Subject in case of any adverse event occurring during the Clinical Trial. The Sponsor shall bear the cost of medical care extended to the Clinical Trial Subjects.

INVESTIGATOR shall promptly contact ERGOMED and Sponsor to report any adverse event experienced by any Clinical Trial Subject as and when required by the Regulations and the Protocol.

INVESTIGATOR shall submit to ERGOMED and the Sponsor a summary of the adverse event, summary of the medical care provided along with all associated documentation (e.g. lab reports, death or injury summary from the attending medical practitioner, operative reports etc.) for each adverse event. INVESTIGATOR shall respond to all requests for follow-up information from ERGOMED. The INVESTIGATOR shall also assist ERGOMED and the Sponsor for preparation of any reports for submissions to the Regulatory Authority in accordance with applicable Regulations.

In case of Serious Adverse Events, the INVESTIGATOR shall within twenty-four hours of occurrence of such incidents, shall notify the Regulatory Authority, IRB, ERGOMED and the Sponsor in writing. The INVESTIGATOR shall submit a detailed report of the Serious Adverse Event to the Regulatory Authority, the chairperson of the IRB, head of the INSTITUTION where the Clinical Trial has been conducted, ERGOMED and the Sponsor within fourteen days of the occurrence of the Serious Adverse Event.

- 2.17. The Sponsor shall be responsible for providing compensation to the Clinical Trial Subjects as determined by the IRB in case of Serious Adverse Events in accordance with Regulations.
- 2.18. In addition to the obligation contained under Section 4.2 below, the INVESTIGATOR shall conduct the Clinical Trial in compliance with the Protocol and applicable Regulations. The INVESTIGATOR shall document and provide a rationale for any deviation from the Protocol and applicable Regulations and, when possible, describe the immediate remediation measures taken to re-establish the safety and rights of the Clinical Trial Subjects. The INVESTIGATOR shall contact ERGOMED and report any suspected serious breach immediately and no later than twenty-four hours after the event comes to the knowledge of the INVESTIGATOR and/or INVESTIGATOR's team. Any reporting to the relevant regulatory authorities shall be performed per local regulatory requirements and by the responsible party. The INSTITUTION

shall have implemented a procedure to ensure timely identification of a suspected serious breach committed by the INVESTIGATOR, INVESTIGATOR's team, and the INSTITUTION's and/or INVESTIGATOR's service providers.

- 2.19. INSTITUTION shall promptly inform Sponsor and ERGOMED of any intended or actual inspection, written inquiry and/or visit to the trial site at the INSTITUTION by any Regulatory Authority and forward to Sponsor and ERGOMED copies of any correspondence from any such regulatory authority relating to the Clinical Trial.

INSTITUTION shall use all reasonable endeavours to ensure that Sponsor and ERGOMED may have a representative present during any such visit. INSTITUTION and INVESTIGATOR agree that during inspection by any regulatory authority concerning the Services or Clinical Trial any of them shall not disclose information and materials that are not required to be disclosed to such regulatory authority, without the prior written consent of ERGOMED, which consent shall not be unreasonably withheld or delayed.

- 2.20. INSTITUTION shall permit Sponsor and ERGOMED to examine the conduct of the Clinical Trial and the premises of INSTITUTION upon 3 (three) days' advance notice during regular business hours to determine whether the Clinical Trial is being conducted in accordance with the requirements set out in this Agreement.
- 2.21. INSTITUTION shall immediately notify Sponsor and ERGOMED if INVESTIGATOR is no longer able for whatever reason to act as INVESTIGATOR.
- 2.22. INSTITUTION shall ensure that the preparation, storage and/or testing of any Clinical Trial Product during the course of the Clinical Trial at the INSTITUTION is carried out in accordance with the Protocol and all the Regulations.

INSTITUTION shall bear all risk of loss or damage to the Clinical Trial Product provided by ERGOMED or Sponsor while the Clinical Trial Product is in the control or possession of INSTITUTION.

- 2.23. INSTITUTION and INVESTIGATOR acknowledge that the Sponsor is and shall at all times remain the sole owner of the Clinical Trial Product.

ERGOMED or Sponsor shall provide INSTITUTION with the required quantities of the Clinical Trial Product, at no charge, for the INSTITUTION to conduct the Clinical Trial.

Neither INSTITUTION nor INVESTIGATOR shall permit the Clinical Trial Product to be used for any purpose other than the conduct of the Clinical Trial and upon termination or expiration of this Agreement all unused Clinical Trial Product shall, at Sponsor's option and expense, either be returned to Sponsor or disposed of in accordance with the Protocol or Sponsor's instructions. Detailed records of stocks and use of the Clinical Trial Product shall be maintained by the INSTITUTION and shall be submitted to ERGOMED or the Sponsor upon request.

- 2.24. Neither the INSTITUTION nor INVESTIGATOR shall during the term of this Agreement conduct any other trial which might hinder their ability to conduct the Clinical Trial in line with the Protocol.
- 2.25. Upon Sponsor's request, INVESTIGATOR shall complete and return to ERGOMED or the Sponsor in a timely manner, financial certification or disclosure forms or any updates thereof, as applicable, provided to the INVESTIGATOR by ERGOMED or the Sponsor.

INSTITUTION and INVESTIGATOR shall ensure that other members of INVESTIGATOR's team, performing any functions related to the Clinical Trial also complete and return all such financial certification/disclosure forms, if so required by the Sponsor.

- 2.26. According to the applicable Regulations in force and as per agreement with the Sponsor regarding Clinical Trial archiving period INSTITUTION and INVESTIGATOR shall retain all Clinical Trial records for 25 (twenty-five) years after the end of the Clinical Trial.

INSTITUTION and/or INVESTIGATOR, as applicable, shall contact ERGOMED and/or Sponsor at least 90 (ninety) days before the planned destruction of any Clinical Trial records, at which time ERGOMED or Sponsor may require that INSTITUTION and/or INVESTIGATOR deliver such records to ERGOMED and/or Sponsor, at the Sponsor's expense.

INSTITUTION and/or INVESTIGATOR shall notify ERGOMED and/or Sponsor immediately in writing of any accidental loss or destruction of Clinical Trial records.

Article 3

Compensation and expenses

- 3.1. As compensation for the conduct of the Clinical Trial as referred to in this Agreement by INSTITUTION and INVESTIGATOR, ERGOMED shall pay to the INSTITUTION the gross fee, GST excluded (if applicable) as indicated in Schedule II herein attached and made an integral part of this Agreement. This gross fee includes any and all taxes that may be applicable anywhere anytime and it is specifically agreed that any such taxes shall be the sole responsibility of the INSTITUTION and of the INVESTIGATOR who shall both timely pay all such taxes for which they are liable. INSTITUTION shall have the responsibility and the obligation to make proper and timely disbursements of funds to all appropriate parties involved in the Clinical Trial.
- 3.2. It is agreed that payment of the sums due under this Agreement shall be payable by ERGOMED by wire transfer at the bank account indicated in the INSTITUTION's invoice and within 30 (thirty) days from the invoice receipt.
- 3.3. In case of the Sponsor's material failure to meet its obligations towards ERGOMED, ERGOMED retains the right to withhold payments to the INSTITUTION and the INVESTIGATOR until Sponsor satisfies its obligations.
- 3.4. Prices in Schedule II are GST excluded.
- 3.5. The INSTITUTION shall issue all invoices under this Agreement to Ergomed Clinical Research Private Limited and deliver to [sitepayments@ergomedgroup.com](mailto:tositepayments@ergomedgroup.com).
- 3.6. Unless otherwise agreed in writing and approved by Sponsor, payments of the sums due under this Agreement shall be made according to the attached Schedule II.
- 3.7. If a dispute arises between the Parties in respect of any part of an invoice, ERGOMED shall: (i) notify INSTITUTION promptly of the particulars of the dispute, and (ii) may withhold payment of the disputed part of the invoice provided that ERGOMED and the INSTITUTION and INVESTIGATOR respectively endeavour promptly and in good faith to resolve the dispute.
- 3.8. In undertaking to perform the Services for ERGOMED, it is understood that INSTITUTION, INVESTIGATOR and INVESTIGATOR's team act as independent contractors without the

capacity to legally bind ERGOMED or the Sponsor and that INVESTIGATOR and INVESTIGATOR's team are doing so as an employee of the INSTITUTION and not as an employee of ERGOMED.

Article 4

Regulatory Review, Opinion from Ethics Committee

- 4.1 The INSTITUTION shall ensure that the IRB holds a valid registration as per applicable Regulations during the tenure of the Clinical Trial.
- 4.2 Until all Parties have obtained all required documentation from the IRB/EC (where necessary) and all required approvals (in writing) regarding the terms and conditions of Clinical Trial, including the Informed Consent Form, related instructions for use and the Protocol from the competent IRB / EC, ERGOMED and/or Sponsor shall not supply the Clinical Trial Product to INSTITUTION, and INSTITUTION and INVESTIGATOR shall not Enrol any Clinical Trial Subject and shall ensure that neither administration of the Clinical Trial Product to any Clinical Trial Subject nor any other clinical intervention mandated by the Protocol takes place in relation to any such Clinical Trial Subject.
- 4.3 All modifications to the Protocol shall be made by the Sponsor and implemented by the INVESTIGATOR after receipt of necessary regulatory or IRB/EC approvals. Neither INSTITUTION nor INVESTIGATOR shall consent to any change in the Protocol requested by a relevant EC without the prior written consent of the Sponsor. INSTITUTION shall promptly forward a copy of any such change in the Protocol requested by a relevant IRB/EC to the Sponsor and ERGOMED.
- 4.4 INSTITUTION and INVESTIGATOR shall promptly forward to ERGOMED and Sponsor copies of all correspondence to or from regulatory authorities and IRB/ECs which concern the Clinical Trial.

Article 5

Data Protection

- 5.1 For the purpose of this Agreement the terms Processing, Controller, Processor, Recipient, Personal Data and Personal Data Breach, shall have the same meaning ascribed to them in Data Protection Laws, especially in GDPR.
- 5.2 The Parties agree to adhere to the principles of confidentiality in relation to Clinical Trial Subjects and at all times comply with applicable Data Protection Laws, especially GDPR and DPDPA when Processing Personal Data in connection with this Agreement. The Personal Data protection measures during the Processing and description of Personal Data Processing are described in Schedules III and IV.
- 5.3 INVESTIGATOR Processes Clinical Trial Subjects' Personal Data in full detail. Clinical Trial Subjects' Personal Data has to be pseudonymised before providing it to ERGOMED and/or Sponsor, i.e. Clinical Trial Subjects are given an identifier by which they are known in a system, which is typically a number – key-coded data. List with the codes and the Clinical Trial Subjects' details is kept only with INVESTIGATOR in order to link the Clinical Trial Subjects to their Personal Data.

Unless pseudonymised, Clinical Trial Subjects' Personal Data shall not be disclosed to ERGOMED or to Sponsor by INVESTIGATOR or INSTITUTION save where this is required to satisfy the requirements of the Protocol or for the purpose of monitoring or adverse event reporting, or in relation to a claim or proceeding brought by a Clinical Trial Subject in connection with the Clinical Trial.

Consequently, ERGOMED and Sponsor shall not disclose the identity of Clinical Trial Subjects to third parties without prior written consent of the Clinical Trial Subject in question except as permitted by and in accordance with Regulations.

INVESTIGATOR shall be the point of contact for any Clinical Trial Subject's data protection related requests (including, but not limiting, to fulfil the Clinical Trial Subject's GDPR rights) concerning the Parties or Sponsor in connection with the Clinical Trial. INVESTIGATOR shall be primarily responsible to handle such requests (including sharing such requests with Sponsor and ERGOMED with compliance with the Regulations, specifically the pseudonymization of Clinical Trial Subject's personal data, where required) and communicate with Clinical Trial Subjects. Sponsor and ERGOMED shall provide reasonable assistance where required to ensure compliance with Clinical Trial Subject's rights under applicable Data Protection Laws.

- 5.4 INVESTIGATOR hereby confirms that she fully understands and has been properly informed that the conclusion and the performance of this Agreement and the conduct of the Clinical Trial as per the Regulations require the Sponsor and ERGOMED to Process her Personal Data. Depending on Sponsor's decision to file for submission for marketing application, necessary Processing may include the transfer of her Personal Data to countries outside India in accordance with applicable Regulations. By entering into this Agreement, the INVESTIGATOR explicitly agrees with such transfers of her Personal Data to the extent necessary for the conclusion and the performance of this Agreement and the conduct of the Clinical Trial as per the Regulations. Such Personal Data may include names, contact information, work experience, qualifications, publications, resumes, educational background, information on performance and professional capabilities and applicable invoicing details.

INSTITUTION and INVESTIGATOR agree to inform the INVESTIGATOR's team about the Processing of INVESTIGATOR's team Personal Data and to establish proper arrangement of their relations with the INVESTIGATOR's team for such Processing. Depending on Sponsor's location and its decision to file for submission for marketing application, Processing necessary for the conclusion and the performance of this Agreement and the conduct of the Clinical Trial as per the Regulations may include the transfer of their Personal Data to countries outside the EU/EEA, which do not ensure adequate level of Personal Data protection as per GDPR. INSTITUTION and INVESTIGATOR shall ensure that INVESTIGATOR's team is aware that their Personal Data shall be Processed for the below mentioned purposes. Any person who does not fully agree with the Processing described should not be involved in any capacity in the INVESTIGATOR's team.

ERGOMED shall provide the INVESTIGATOR and INVESTIGATOR's team with the Personal Data information notice that contains information about their Personal Data Processed and their rights (e.g. access right, portability, rectification) so that Sponsor and / or ERGOMED comply with their obligation under applicable Data Protection Laws.

- 5.5 The Sponsor and ERGOMED Process Personal Data of the INVESTIGATOR and INVESTIGATOR's team for the following specific purposes, where:
- the Sponsor is the Controller:

- (i) ensuring proper conduct of the Clinical Trial;
 - (ii) review by a regulatory authority, Sponsor, ERGOMED or their agents;
 - (iii) publication on www.clinicaltrials.gov, other public websites and public portals for clinical documents of EMA and other relevant agencies that inform about clinical trials and participating investigators and corresponding clinical trial results;
 - (iv) satisfying legal or regulatory requirements e.g. anti-corruption compliance.
- ERGOMED is the Controller:
 - (i) maintaining in databases to facilitate selection of investigators and sites in future clinical trials;
 - (ii) conclusion and performance of this Agreement;
 - (iii) ERGOMED's legal obligations as far as such exist or may be imposed under the Regulations to ERGOMED (for example, tax obligations);
 - (iv) for the establishment, exercise or defence of legal claims.

ERGOMED's, INSTITUTION's and INVESTIGATOR's legal basis for Processing in the role of the Processor is the performance of a contract.

Article 6

Intellectual Property

- 6.1. The Parties hereby agree that the Sponsor shall at all times retain ownership of any know-how, trade secrets, developments, discoveries, inventions, innovations or improvements (whether or not patentable) conceived or first reduced to practice, or deriving therefrom, in the performance of Services under this Agreement, in the performance of the Clinical Trial, or as a result of using data from the Clinical Trial by INSTITUTION, its employees or INVESTIGATOR (hereinafter: the "**Intellectual Property**") and the INSTITUTION and INVESTIGATOR have no rights to any such Intellectual Property.

For the avoidance of doubt, the INSTITUTION and INVESTIGATOR hereby grant to Sponsor any and all right, title and interest in any and to any Intellectual Property. INVESTIGATOR and INSTITUTION shall assign and deliver to Sponsor all documents and do all such things as may be necessary or appropriate to vest in Sponsor all rights, title and interest in and to such Intellectual Property. INVESTIGATOR and INSTITUTION shall promptly disclose to the Sponsor any such Intellectual Property.

Upon the request of the Sponsor INVESTIGATOR and INSTITUTION shall assist the Sponsor in the preparation, filing and prosecution of such patent applications; INVESTIGATOR and INSTITUTION further agree to execute and deliver any and all instruments necessary to effectuate the ownership of such patent applications and to enable the Sponsor to file and prosecute such patent applications in any country.

- 6.2. INSTITUTION and INVESTIGATOR agree that any and all works, recommendations, advices, observations and conclusions, rendered, obtained, generated, conceived or derived, directly or indirectly, by INSTITUTION and/or INVESTIGATOR during the course of the performance of Services under this Agreement, in performance of the Clinical Trial, or as a result of using data from the Clinical Trial, including, without limitation, clinical and other data (including without limitation, written, printed, graphic, video and audio material, and information contained in any computer database or computer readable form) shall be Sponsor's absolute and exclusive property, who shall be free to use it as it deems fit for any purpose whatsoever.

INSTITUTION and INVESTIGATOR agree that they assert no claim to rights in technology and materials owned by ERGOMED or the Sponsor.

- 6.3. INSTITUTION or INVESTIGATOR may be allowed to present and publish data resulting from the Clinical Trial pursuant to the Sponsor's publication policies and upon obtaining prior expressed written approval from the Sponsor for any such presentation or publication.

Any material prepared for publication or presentation shall be submitted to the Sponsor for review and comment at least 60 (sixty) days prior to submission for publication. INSTITUTION and/or INVESTIGATOR shall modify the publication or presentation material according to the comments provided by the Sponsor.

- 6.4. INSTITUTION and/or INVESTIGATOR further agree to delete information identified by ERGOMED or the Sponsor as confidential, prior to submitting such material for publication or presentation. During the period for review of a proposed publication or presentation material, the Sponsor shall be entitled to request a delay of publishing such materials for a period of up to 6 (six) months from the date of first submission to the Sponsor in order to enable the Sponsor to take steps to protect its proprietary information and/or Intellectual Property.

INSTITUTION and/or INVESTIGATOR shall not unreasonably withhold or delay their consent to a request from the Sponsor for an exceptional additional delay if, in the reasonable opinion of the Sponsor, the Sponsor's proprietary information and/or intellectual property rights and know-how might otherwise be compromised or lost.

- 6.5. If the Clinical Trial is multi-centre, any publication based on the results obtained at the INSTITUTION (or a group of sites) shall not be made before the first multi-centre publication. In case of presentation or publication of such data INSTITUTION and INVESTIGATOR shall be bound by the confidentiality of Article 7 of this Agreement and subject to preserving Sponsor's rights in Articles 6.1 and 6.2. herein.

- 6.6. INSTITUTION and INVESTIGATOR shall not, and shall ensure that their respective personnel do not, engage in interviews or other contacts with the media, including but not limited to newspapers, radio, television and the Internet, related to the Clinical Trial and the Clinical Trial Product without the prior written consent of the Sponsor. This provision does not prohibit publication, presentation or other public disclosure in accordance with Sections 6.3.

Article 7

Confidentiality

- 7.1. INSTITUTION and INVESTIGATOR shall hold in strict confidence any and all information (i) acquired by the INSTITUTION and/or INVESTIGATOR from ERGOMED and/or the Sponsor in reference to the Clinical Trial Product, the Sponsor or ERGOMED, or the Services performed under this Agreement or the Clinical Trial and (ii) developed by the INSTITUTION and/or INVESTIGATOR in the performance of the Services under this Agreement or the Clinical Trial (hereinafter: "**Confidential Information**").
- 7.2. INSTITUTION and INVESTIGATOR undertake to permit access to the Confidential Information only to those employees of the INSTITUTION or members of the INVESTIGATOR's team who reasonably need access to such information for the carrying out of the duties under this Agreement and who have signed confidentiality agreements containing,

or are otherwise bound by, confidentiality obligations at least as restrictive as those contained herein.

INSTITUTION and INVESTIGATOR agree to handle and shall ensure that members of INVESTIGATOR's team:

- (i) handle Confidential Information with the reasonable degree of care;
- (ii) take precautions as necessary and appropriate to guard the confidentiality of Confidential Information and any inadvertent disclosure thereof;
- (iii) use such Confidential Information only for the performance of their obligations under this Agreement.

7.3. This Article shall not apply to information:

- (i) which was known to INSTITUTION or INVESTIGATOR prior to its receipt from ERGOMED or the Sponsor, and INSTITUTION or INVESTIGATOR is able to so demonstrate through bona fide written records of such receipt,
- (ii) which is or lawfully becomes generally available to the public as evidenced by objective public record,
- (iii) which is lawfully acquired from third parties who have a right to disclose such information, or
- (iv) which INSTITUTION or INVESTIGATOR is required by law to release, provided that INSTITUTION or INVESTIGATOR gives advance written notice of such requirement so that Sponsor has the opportunity to object to such disclosure.

7.4. Nothing herein shall be construed as prohibiting the Sponsor from reporting on this Clinical Trial to a governmental or regulatory agency or from exercising its right in its Confidential Information as it deems appropriate in its sole discretion.

Article 8

Insurance and Indemnification

8.1. INSTITUTION shall defend, indemnify, save and hold harmless the Sponsor, ERGOMED, their affiliated entities and respective affiliates, subsidiaries, directors, officers, employees, contractors, stockholders, agents, and successors and assigns from and against any and all claims, demands, suits, actions, causes of action, losses, damages, fines and liabilities, including court costs and reasonable attorneys' fees ("Losses") resulting from or arising out of any third party claims, actions or proceedings relating to any INSTITUTION's and/or the INVESTIGATOR's and/or the INVESTIGATOR's team's:

- (i) failure to follow any Regulations, including applicable federal, state or local laws, regulations, and guidelines, or to conform to reasonable and prudent clinical practices, including GCPs as applicable to clinical studies for the Clinical Trial Product;
- (ii) wrongful or negligent acts or omissions, or wilful malfeasance or misuse of the Clinical Trial Product;
- (iii) failure to comply with the Approved Protocol;
- (iv) failure to report Adverse Events and Serious Adverse Events within prescribed timelines;
- (v) failure to provide adequate and prompt medical care to Clinical Trial Subjects during adverse events;

- (vi) failure to follow the Protocol or other written recommendations or instructions provided to the INSTITUTION and/or the INVESTIGATOR and/or the INVESTIGATOR's team by ERGOMED or the Sponsor.
- 8.2. INVESTIGATOR shall maintain insurance coverage. The INVESTIGATOR shall provide ERGOMED with a certificate of insurance within 30 (thirty) days of the date of the Agreement. (This clause may not be applicable to Indian Investigators)
- 8.3. ERGOMED shall ensure that the Sponsor obtains appropriate insurance cover or provides an indemnity satisfactory to the INSTITUTION and INVESTIGATOR and for providing compensation and medical care to injured Clinical Trial Subjects in respect of its potential liability under the Clinical Trial.

ERGOMED shall produce to the INSTITUTION, on request, copy of an adequate insurance policy covering Sponsor's liability vis-à-vis Clinical Trial Subject in compliance with applicable Indian law.
- 8.4. ERGOMED shall maintain an appropriate insurance coverage in respect of its potential liability under this Agreement. ERGOMED shall defend, indemnify, save and hold harmless the INSTITUTION and the INVESTIGATOR from and against any and all Losses resulting from or arising out of any third party claims, actions or proceedings relating to any ERGOMED's wrongful or negligent acts or omissions.
- 8.5. The INSTITUTION shall maintain professional liability insurance coverage and general liability insurance coverage (including contractual liability) that does not exclude clinical studies as well as the DPDPA liability, sufficient to cover the INSTITUTION's indemnification obligations hereunder. If the policy is a claims-made policy, the INSTITUTION shall extend the coverage period of such insurance coverage, for an additional 5 (five) years after completion of the Clinical Trial. The INSTITUTION shall provide ERGOMED with a certificate of insurance within 30 (thirty) days of the date of the Agreement. (This clause may not be applicable to Indian Institutes)
- 8.6. INSTITUTION and INVESTIGATOR acknowledge that the Sponsor has engaged ERGOMED to manage the Clinical Trial, so ERGOMED has performed no independent research or analysis regarding the safety or efficacy of the Clinical Trial Product, materials or treatment procedures that are to be administered pursuant to the Clinical Trial and, therefore, ERGOMED makes no warranties, expressed or implied concerning the Clinical Trial Product, materials, treatment procedures, results to be obtained in administering the Clinical Trial Product, or the Clinical Trial Product's fitness for any particular purpose.
- 8.7. ERGOMED expressly disclaims any liability in connection with the Clinical Trial Product caused by, or allegedly caused by, the use or misuse of the Clinical Trial Product other than liability for death, personal injury or loss of or damage to property which liability is the result of gross negligence or wilful misconduct on the part of ERGOMED.
- 8.8. Nothing in this Article 8 may be construed so as to restrict or exclude the liability of INSTITUTION or INVESTIGATOR in relation to death or personal injury caused by the negligence of such Party or its employees respectively or to restrict or exclude any other liability of INSTITUTION or INVESTIGATOR which cannot be so restricted or excluded in law.
- 8.9. INSTITUTION and INVESTIGATOR are obliged to immediately, in written form, inform ERGOMED of any claim on existence of any personal injury, death or damages, and shall allow

the Sponsor and/or ERGOMED to resolve such claim (including settlement deal) in accordance with applicable laws and shall cooperate with the Sponsor or ERGOMED in resolving of such claim.

Sponsor and ERGOMED shall have exclusive control with respect to resolving such claim or petition, including any settlement, however with limitation that such settlement shall not include recognition of the responsibility of the INSTITUTION and/or the INVESTIGATOR and their associates without their prior written approval, which shall not be withheld without valid reason.

Article 9

Anti-Corruption (Anti-Kickback and Anti-Bribery)

- 9.1. The INVESTIGATOR and the INSTITUTION agree that their judgment with respect to the advice and care of each Clinical Trial Subject shall not be affected by the compensation they receive under this Agreement, that such compensation does not exceed the fair market value of the services they are providing, and that no payments are being provided to them for the purpose of inducing them to purchase or prescribe any drugs, devices or products.
- 9.2. The INVESTIGATOR and the INSTITUTION agree that they shall not bill any Clinical Trial Subject, insurer, or governmental agency for any visits, services or expenses incurred during the Clinical Trial for which they have received compensation from ERGOMED.
- 9.3. Each Party, in performing this Agreement, represents and warrants that it shall:
 - a) fully and absolutely comply with the provisions of any applicable legislation on anti-bribery/anti-corruption prevention as well as with the principles of international anti-bribery/anti-corruption legislations such as Prevention of Corruption Act, 1988, OECD Anti Bribery Convention or Combating Bribery of Foreign Public Officials in International Business Transactions, UK Bribery Act, US Foreign Corrupt Practices Act, which are in force from time to time (“**Anti-Bribery Regulations**”);
 - b) adopt all necessary measures to prevent violation to the Anti-Bribery Regulations;
 - c) not, in the conduct of the performance of the Services under this Agreement, offer, pay, give, or promise to pay or give, directly or indirectly, any payment or gift of money or thing of value to: (a) any government official to influence any acts or decisions of such official or to induce such official to use his/her influence with any government to effect or influence the decision of such government in order to assist the Party in its performance of the obligations under this Agreement or to benefit any of the Parties; (b) any political party or candidate for public office for such purpose; or (c) any person if either Party knows or has reason to know that such money or thing of value shall be offered, promised, paid, or given, directly or indirectly, to any official, political party, or candidate for such purpose.
- 9.4. The defaulting Party shall hold harmless and indemnify the other Parties and the Sponsor from any and all claim, expense, fine, sanction, obligations or consequences that may arise from violation of this Article and/or the Anti-Bribery Regulations.
- 9.5. A violation or a threatened violation of this Article and/or the Anti-Bribery Regulations shall constitute a material breach under this Agreement and in addition to other rights or remedies under this Agreement or at law, the non-defaulting Party may terminate this Agreement with

immediate effect if the defaulting Party breaches any of the representations or warranties contained in this Article.

Article 10

Term and Termination

- 10.1. This Agreement shall become effective on the date of its signing by all Parties and if signed on the different dates then on the latest signature date (“**Effective Date**”) and shall remain in full force and effect until the full and satisfactory completion of the Services by the INSTITUTION and INVESTIGATOR.
- 10.2. ERGOMED may terminate this Agreement prior to its expiration with a written notice to the other Parties and a notice period of not less than 30 (thirty) calendar days.
- 10.3. ERGOMED may terminate this Agreement prior to the full and satisfactory completion of the Services by the INSTITUTION and INVESTIGATOR by written notice and immediate effect for any of the following reasons:
 - A. In case the Sponsor has terminated the relevant Agreement with ERGOMED and / or has ceased any further activity on the Clinical Trial and / or has requested to stop Enrolment regardless of the reason given to ERGOMED by the Sponsor;
 - B. Continuous and / or repetitive and /or material breach of any of the INSTITUTION’s and / or INVESTIGATOR’s obligations stipulated herein. For the purpose of this Agreement, the following shall, among other, be considered as the material breach of this Agreement:
 - (i) INVESTIGATOR and/or INSTITUTION prevent access to ERGOMED’s employees or contractors or any third persons authorized by ERGOMED and / or the Sponsor to any and all original medical records necessary to verify entries on Clinical Trial Case Report Forms;
 - (ii) INVESTIGATOR, her associates, or any other person engaged in this Clinical Trial (excluding Clinical Trial Subjects) are unavailable upon reasonable notice by ERGOMED and/or the Sponsor, to meet with ERGOMED’s and/or the Sponsor’s representative during the course of the Clinical Trial, as necessary, to discuss information relevant to the Clinical Trial;
 - (iii) Case Report Forms have not been legibly completed and / or forwarded by the INVESTIGATOR to ERGOMED or to its designated representative, as appropriate within 60 (sixty) days of each Clinical Trial Subject’s completion date.
 - C. In case INVESTIGATOR does not recruit any Clinical Trial Subject within 60 (sixty) days from the day of the initial visit;
 - D. In case the regulatory and / or IRB/EC: (i) has not issued the permit or approval for conducting of the Clinical Trial; or (ii) loss of such permit or approval;
 - E. Determination by ERGOMED and/or the Sponsor that the INVESTIGATOR, after a reasonable opportunity, is unable, for any reason to act as INVESTIGATOR and/or to

satisfactorily perform the Clinical Trial as required by the Protocol and a suitable INVESTIGATOR replacement is not made timely.

- 10.4. In the event that ERGOMED chooses to exercise its right to terminate this Agreement, the INVESTIGATOR shall, immediately upon receipt of ERGOMED's notice to terminate, cease Enrolling Clinical Trial Subjects into the Clinical Trial and shall discontinue conducting Clinical Trial procedures, to the extent medically possible.
- 10.5. The rights and obligations of the Parties under any provision of this Agreement, which by its term is intended to survive beyond the term of this Agreement, including but not limited to Article 5 (Data Protection), Article 6 (Intellectual Property), Article 7 (Confidentiality) and Article 8 (Insurance and Indemnification), shall continue notwithstanding the termination or expiration of this Agreement for any reason.
- 10.6. In the event of early termination, the sum payable under this Agreement shall be limited to pro-rated fees based on actual work performed pursuant to the Protocol.
- 10.7. INSTITUTION and INVESTIGATOR shall return to ERGOMED any unused Clinical Trial Product and all Clinical Trial materials shall, at the Sponsor's option and expense, either be returned to the Sponsor or disposed of in accordance with the Protocol or the Sponsor's written instructions.

Article 11

Final Provisions

- 11.1. Neither Party may delegate their obligations or assign their rights hereunder without the prior written consent of the Sponsor. ERGOMED may assign this Agreement with Sponsor's prior written consent and without the consent of INSTITUTION or INVESTIGATOR.
- 11.2. Any and all additions and/or amendments to this Agreement shall be in writing, numbered, dated and signed by the authorized representatives of all Parties.
- 11.3. In the case of inconsistency between the Protocol and the other terms of this Agreement, or any other document incorporated therein, the terms of the Protocol shall prevail to the extent applicable to the medical treatment of Clinical Trial Subjects but no further. In respect of other inconsistencies, the Agreement shall prevail.
- 11.4. Any and all disputes arising out of or in connection with the Agreement shall be settled by an amicable effort of the Parties.
- 11.5. Any dispute, which is not amicably settled by such efforts of the Parties, shall be finally resolved under the Rules of the Indian by 1 (one) arbitrator appointed pursuant to such Rules. The seat of such arbitration shall be in Tamaka, Kolar, Karnataka, India. The language of arbitral proceedings shall be English.
- 11.6. This Agreement and all disputes thereof shall be governed by and construed in accordance with the laws of India.
- 11.7. If any provision of this Agreement should be deemed invalid or legally unenforceable, such provision shall not affect the validity and/or enforceability of any other provision(s) of this

Agreement or the Agreement as a whole. The Parties shall, in such case, replace the invalid provision with a valid one that best expresses their original intent.

- 11.8. This Agreement is being executed in 3 (three) identical copies, of which each Party shall keep 1 (one) copy.
- 11.9. The Parties agree that Sponsor is an intended third party beneficiary of this Agreement, with full benefits and full rights of enforcement. Except for the Sponsor, the Parties do not intend that any term of this Agreement shall be enforceable by any person who is not a Party to this Agreement.
- 11.10. In this Agreement, the words "including" and "includes" mean "including without limitation."
- 11.11. All notices, statements, demands, requests, consents, communications and certificates from any Party hereto to the other shall be made in writing unless specified to the contrary herein and sent by fax, certified mail, return receipt requested, hand delivered or by FedEx® or similar overnight delivery service for which a receipt is made to the Parties, addressed as follows:

- (a) If intended for ERGOMED

Ergomed Clinical Research Private Limited
91 Springboard Business Hub Private Limited
9th Floor, Sadanand Business Centre, Sr. No.104/1, NH 48, Service Road,
Baner, Pune Maharashtra 411045

with copy to: legal@Ergomedgroup.com

- (b) If intended for Sponsor:

Neuraxpharm Pharmaceuticals S.L.
Av. Barcelona, 69. 08970 Sant Joan Despí
Barcelona, Spain
with copy to: fjurado@neuraxpharm.com

- (c) If intended for INSTITUTION:

R.L. Jalappa Hospital and Research Centre, Sri Devaraj Urs Medical College
Tamaka, Kolar, Karnataka 563103
with copy to: dir.research@sduaher.ac.in

Dr Rajesh Venkataraman,
Adichunchanagiri Hospital,
Adichunchanagiri University
B.G Nagara, Mandya, Karnataka -571 448.
With copy to: drrajesh.ahrc@gmail.com

- (d) If intended for INVESTIGATOR:

Dr. Bhuma Vengamma
R.L. Jalappa Hospital and Research Centre, Sri Devaraj Urs Medical College
Tamaka, Kolar, Karnataka 563103


with copy to: vicechancellor@sduaher.ac.in)

or such other addresses as either Party hereto may from time to time direct by service of notice to the other Party as provided above. Any such notices, statements, demands, requests, consents, communications or certificates shall be deemed given on the date received.


- 11.12. The Parties agree that this Agreement may be executed by way of electronic signatures and that the electronic signature has the same binding effect as a physical signature. For the avoidance of doubt, the Parties agree that this Agreement, or any part thereof, shall not be denied legal effect, validity or enforceability solely on the ground that it is in the form of an electronic record.

Signature page follows


SIGNED on behalf of **ERGOMED**:


Name: _____ Date: 05 Dec 2024
Title: Koushik Ganguly
Office Director / Sr. Project Director


SIGNED by **ERGOMED** on behalf of
Sponsor:


Name: _____ Date: 05 Dec 2024
Title: Koushik Ganguly
Office Director / Sr. Project Director

SIGNED by the **INSTITUTION**:


Name: Dr. Kalyani R Date: 11/12/24
Title: Director
Research & Development Cell,
SDUAHER

SIGNED by the **INVESTIGATOR**:


Name: Dr Bhuma Vengamma Date: 11th Dec 2024
Title: Vice-Chancellor, SDUAHER

SCHEDULE I – PROTOCOL
- Provided under a separate cover -



SCHEDULE II – PAYMENT TERMS AND BUDGET

1. Enrollment target

- a. The INVESTIGATOR shall randomize a minimum of four (4) and up to eight (8) Clinical Trial Participants (“Participants”) in the Clinical Trial as agreed and authorized by SPONSOR through ERGOMED. The INVESTIGATOR shall not randomize any Participants above the enrolment target, unless expressly authorized in writing by the SPONSOR, through ERGOMED.
- b. SPONSOR, through ERGOMED, may increase the enrolment target through a written notification sent to the INSTITUTION and INVESTIGATOR which includes the updated enrolment target. The Parties agree that such changes will not require any formal amendments to this Agreement.
- c. The INSTITUTION and INVESTIGATOR acknowledge that enrollment of Participants may be competitive among all Clinical Trial Sites, and as result, the INSTITUTION and INVESTIGATOR shall cease screening and enrolling Participants at any time upon SPONSOR’s direct request, or through ERGOMED.

2. Compensation and Payment terms

- a. As compensation to the INSTITUTION and INVESTIGATOR for conducting the Clinical Trial, SPONSOR, through ERGOMED acting as its paying agent, shall make payments each quarter by electronic wire transfer to SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH (“Payee”) in line (1) with the amounts and in the currency listed in **Appendix 1 – Clinical Trial Budget (“Budget”)**, and (2) with the Payment terms defined herein.
- b. SPONSOR, through ERGOMED, shall generate within 15 business days of the end of each calendar quarter a proforma invoice covering activities completed at the site based on EDC data entered by the INSTITUTION or INVESTIGATOR, and verified by ERGOMED, which will be sent to the Payee for verification and approval.
- c. If the Payee does not raise any queries to SPONSOR through ERGOMED within 10 business days of receipt, SPONSOR will consider the proforma invoice as approved. Any queries raised by the Payee will be resolved by SPONSOR, through ERGOMED, and by the Payee in good faith in line with Article 3 of this Agreement.
- d. Upon approval, SPONSOR through ERGOMED, will process and initiate the payments for such activities within 30 calendar days at the rates set forth in the Budget and based on the terms of this Schedule II.
- e. For activities payable upon receipt of an invoice, SPONSOR through ERGOMED, will pay the Payee within 30 calendar days of receipt of a correct invoice from the Payee, subject to a verification of the invoice by SPONSOR, through ERGOMED.
- f. Payee will only be compensated for services that have been properly performed in accordance with the Protocol and this Agreement, and payments are dependent upon completion of CRFs/eCRFs, reports, and other documents pursuant to this Agreement being submitted in a timely and satisfactory manner.

- g. SPONSOR, through ERGOMED, will not pay for any visits performed in relation to any Participants who do not conform to the Protocol's inclusion and exclusion criteria or in relation to whom serious violation(s) of the Protocol have been made, if the violation(s) resulted in the withdrawal of the Participant from the Clinical Trial. Payments for Participants who were deemed to have been in violation, may be made up to the point of when the violation occurred, at the sole discretion of the SPONSOR.
- h. All payments shall be performed in line with the following payment terms ("**Payment terms**"):

i.	Per Participant Costs:	Payments will be made on a per Participant per visit basis for visits completed as per EDC data entered during the preceding quarter.
ii.	Screen Failure costs:	<p>Failures at V1 Screening Visit (Onsite) shall be paid as per the Screen Failure rate in the Budget, for any Participant(s) undergoing screening procedures but not randomized to receive the Clinical Trial Product.</p> <p>Payments for screen failures will be limited to one (1) screen failure for every two (2) Participants randomized, up to a limit of four (4) screen failures. Once reached, it will be paid at a rate of one (1) screen failure for every three (3) of Participants randomized.</p> <p>This limit of payable Screen Failures may be increased by written notification sent to the INSTITUTION and INVESTIGATOR by the SPONSOR through ERGOMED, which includes the updated Screen Failure limit. The Parties agree that such changes will not require any formal amendments to this Agreement.</p> <p>Payment of Screen Failure costs shall be made following receipt of a correct and itemized Invoice, subject to SPONSOR's verification through ERGOMED.</p>
iii.	Conditional procedures	<p>Conditional procedures as per the Budget will be reimbursed to the Payee on a per subject per procedure basis for conditional procedures completed in line with the Protocol and this Agreement.</p> <p>Payment shall be made in accordance with the Budget upon receipt of a correct and itemized Invoice detailing Conditional Procedures completed during the preceding quarter, subject to SPONSOR's verification through ERGOMED.</p>
iv.	Participant travel reimbursements:	Sponsor, through ERGOMED, will provide reimbursement for reasonable and documented Participant travel costs incurred by Participants during visits up to the amounts set in the Budget, upon receipt of an invoice detailing actual amounts reimbursed by the Institution to each Participant, subject to SPONSOR's verification through ERGOMED.

		Reasonable costs/expense are defined as standard class public transport, private hire vehicles (taxis), use of a private vehicle (the latter at Local Government Approved Rate(s)), parking, meals and incidentals.
v.	Early withdrawal reimbursement:	<p>An early withdrawal is a Participant who (1) completes Visit 4 and (2) withdraws from participation in the Clinical Trial prior to Visit (“Early Withdrawal”).</p> <p>Payment of the Early Withdrawal Fee shall be made in accordance with the Budget following receipt of a correct and itemized Invoice, subject to SPONSOR’s verification through ERGOMED.</p> <p>Because some of the procedures required by Protocol for Early Withdrawals may have already been performed as part of a standard visit, only those Early Withdrawal procedures not already included in a visit will be reimbursed.</p>
vi.	Safety Follow-up visits:	If a Participant experiences a SAE between Visit 4 and Visit 8 , the Subject must be brought back for a follow-up. If Visit 9/ Safety Follow-up is performed at the Site rather than via a phone call, the Institution will be paid for the Safety Follow-up visit in line with the Budget, upon receipt of a correct and itemized Invoice.
vii.	Unscheduled visits:	<p>An Unscheduled Visit means a Participant visit which is not expressly set forth in the Clinical Trial Plan nor in the Procedures of the Protocol but is otherwise required for the Clinical Trial.</p> <p>SPONSOR will pay through ERGOMED for unscheduled visits approved by the SPONSOR, at the rate determined in the Budget. Payments will be performed following receipt of a correct and itemized Invoice detailing Unscheduled Visits completed during the preceding quarter.</p> <p>Under no circumstances shall Institution be paid for more than one (1) unscheduled visit per randomized subject.</p>
viii.	IRB Fees:	<p>Local IRB/EC Fees will be paid to the Payee on a pass-through basis upon receipt of a correct and itemized invoice from Payee.</p> <p>Following approval by SPONSOR through ERGOMED, any subsequent re-submissions, amendments, or renewals will be reimbursed upon ERGOMED’s receipt of appropriate documentation and invoice.</p>
ix.	Start-up Fee	A one-time Start-up Fee will be paid to Payee upon (1) receipt and approval of all regulatory documents, (2) signature of this Agreement and (3) following the Site’s activation by SPONSOR, through ERGOMED.

		Payment of the Start-up Fee shall be made in accordance with the Budget following receipt of a correct and itemized Invoice, subject to SPONSOR's verification through ERGOMED.
x.	Storage Fees:	A one-time long-term Document Storage/ Record retention Fee will be paid to Payee in line with the Budget upon receipt of an invoice at Study close-out.
xi.	Overhead costs:	All fees in the Budget are inclusive of any overhead costs as incurred by the Institution where applicable.

- i. Final payment will be made to the Payee by SPONSOR, through ERGOMED, when INSTITUTION and/or INVESTIGATOR have cumulatively:
 - i. Completed the Clinical Trial;
 - ii. Satisfactorily accounted for all unused Clinical Trial Product, materials, supplies, and Equipment;
 - iii. Completed CRF / eCRF and for each Clinical Trial Subject in the Clinical Trial;
 - iv. Satisfactorily answered all of SPONSOR and/or ERGOMED inquiries regarding the Clinical Trial; and
 - v. Received confirmation from SPONSOR directly or through ERGOMED that all applicable conditions above have been satisfied in accordance to this Agreement.
- j. Final invoices need to be submitted to SPONSOR, through ERGOMED, for payment no later than within 30 calendar days from the moment SPONSOR directly or through ERGOMED confirmed to INSTITUTION and INVESTIGATOR that all applicable conditions listed above in Schedule II - section 2 i) have been satisfied. SPONSOR, through ERGOMED, will pay the final invoices within 30 calendar days of receipt of a valid invoice.
- k. The Payee will have 30 calendar days from the Final Payment, to inform SPONSOR, through ERGOMED, of any payment discrepancies for consideration. SPONSOR reserves itself the right not to pay through ERGOMED any invoices or discrepancies after this period.

3. Taxes

- a. All agreed upon amounts are NET, and Goods and Services Tax (GST)/Harmonized Sales Tax (HST) is excluded. The Institution acknowledges that the services supplied to SPONSOR are exempt for GST/HST purposes. Alternatively, if the services provided by the INSTITUTION are not exempt (for GST/HST purposes), the supply by the INSTITUTION to SPONSOR is subject to a zero rate of GST/HST as export services. The payment will not be subject to a withholding tax. In the limit of applicable regulation, it is the responsibility of the PAYEE to declare this income and SPONSOR is not liable for any taxes due.
- b. All other taxes, costs, tariffs, duties, social contributions and fixed amounts are included in the payments detailed within Schedule II. The INSTITUTION, INVESTIGATOR, and/or PAYEE are solely responsible for the timely payment of all taxes, costs, tariffs, duties, social contributions and

fixed amounts levied by relevant local, federal, or national authorities for which the INSTITUTION, INVESTIGATOR or PAYEE are liable.

4. Payee details

PAYEE Details	
Type:	INVESTIGATOR / INSTITUTION
Name:	Sri Devaraj Urs Academy of Higher Education and Research
Address:	Tamaka, Kolar, Karnataka, India
Tax ID Nr:	xxxx
PAYEE Bank Account details	
Bank Name:	Kotak Mahindra Bank
Bank and Branch ID Number:	SDUMC branch, ID is 8269
Bank account number / IBAN number	2849611362
BIC / Swift number:	KKBKINBB
Name and details of PAYEE contact responsible for managing invoices and payments:	
First & Last Name:	Dr. Bhuvana K
Job Title:	Chief Co-ordinating Officer Clinical Trial Centre, SUDAHER, Kolar
Email address:	bhuvanak@sduaher.ac.in
Phone number:	9900383738

- a. All payments made by SPONSOR, through ERGOMED, as set forth in this AGREEMENT shall be payable solely to the designated PAYEE above. Any payments made to the PAYEE that are due to any other party performing services in connection with this Clinical Trial shall be settled solely between the PAYEE and such a Party.
- b. The INSTITUTION and INVESTIGATOR certify that the above Payee is the proper Payee to receive payments under this Agreement.

5. Invoicing

- a. Any invoices due under this Agreement shall be issued and sent to:

Issued to Sponsor:	Neuraxpharm Pharmaceuticals S.L. Av. Barcelona, 69. 08970 Sant Joan Despí (Barcelona), Spain Tax ID: B08165789
Sent to ERGOMED:	ERGOMED CLINICAL RESEARCH LIMITED 1 Occam Court, Surrey Research Park, Guildford, GU2 7HJ United Kingdom



To expedite payments, please send an electronic invoice to the following ERGOMED email address:	sitepayments@ergomedgroup.com
---	--

b. Instructions for Processing of Payments

Invoices must include the following information:

- Invoice reference number
- Payee Name (as shown in this Schedule II)
- Payee Address
- Payee Tax ID number
- Protocol number
- Site number
- Date & itemized description of services provided/ invoiced
- Applicable supporting documents/ third party invoices
- Total amount payable

ERGOMED will process on behalf of SPONSOR all payments electronically. Such electronic payments will be sent directly to the Payee's bank account as provided above.



Appendix 1 – Clinical Trial Budget

Budget Information Standard Conditional Overall Currency: INR - Indian Rupee Location: India

Total Cost per Patient: 410,672.44 15,975.00 426,647.44 Overhead Percent: 25.00%

Selected Activities: 234753.95 per patient

Name	ORF	Total	Screen	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Early Termination	Unscheduled	Total	Selected Cost
		Quantity														
Eligibility Criteria	Y	2.00	1.00			1.00									1,270.00	635.00
Informed Consent Form	Y	1.00	1.00												1,439.00	1,439.00
Demographic Data	Y	1.00	1.00												2,226.00	2,226.00
Relevant Medical History	Y	1.00	1.00												1,900.00	1,900.00
Prior/Concomitant Medications (including ASx)	Y	12.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	6,216.00	518.00
Physical Examination	Y	7.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	25,514.00	3,702.00
Neurological Examination	Y	7.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	21,070.00	3,010.00
Vital Signs	Y	8.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	12,488.00	1,561.00
Height	Y	1.00	1.00												880.49	880.49
Weight	Y	3.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2,641.46	880.49
Electrocardiography	Y	8.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	4,800.00	600.00
Safety Laboratory Tests (Hematology)	Y	8.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	11,360.00	1,420.00
Safety Laboratory Tests (Chemistry)	Y	8.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	25,520.00	3,190.00
Safety Laboratory Tests (Urinalysis)	Y	8.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	320.00	40.00
Urine Drug Screen	Y	1.00	1.00												720.00	720.00
HbA1c	Y	1.00	1.00												520.00	520.00
HCV	Y	1.00	1.00												650.00	650.00
HIV	Y	1.00	1.00												520.00	520.00
Randomization	Y	1.00	1.00												716.00	716.00
Access to the Subject Seizure Diary (eDiary) and training	Y	6.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	9,636.00	1,606.00
Subject Seizure Diary Completion	Y	12.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	7,021.00	1,003.00
Collection of Subject Seizure Diary Data	Y	7.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	7,124.00	1,781.00
Assessment of Quality of Life in Epilepsy (QoLE-31 Version 2 OR QoLE-AD-46)	Y	4.00	1.00													
Risk of Suicidality (CSR-S)	Y	12.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	44,172.00	3,681.00
AEs Collection	Y	12.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	6,216.00	518.00
IMP Treatment Compliance	Y	7.00	1.00			1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	14,042.00	2,006.00
TSQM	Y	3.00	1.00												3,345.00	1,115.00
MMAS (6-item)	Y	3.00	1.00												4,386.00	1,462.00
End of Study / ET Documentation	Y	3.00	1.00												14,841.00	4,947.00
Telephone Visit	Y	4.00	1.00	1.00	1.00		1.00				1.00				2,800.00	700.00
															234,753.95	



Selected Other Direct Costs : 93784 per patient

Name	OH?	Total	Screen	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Early Termination	Unscheduled	Total	Selected Cost
Physician Salary (w/o Exam Costs)	Y	12.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	44,712.00	3,726.00
Patient Reimbursement, Per Visit	Y	7.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	10,500.00	1,500.00
Study Coordinator, Per Visit	Y	12.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	34,668.00	2,889.00
Study Drug Accountability	Y	1.00													2,368.00	2,368.00
Distribution of IMP	Y	3.00													1,536.00	512.00
Total															93,784.00	

Selected Conditional Activities and Itemized Other Direct Costs: 12780 per patient

Name	OH?	Total	Screen	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Early Termination	Unscheduled	Total	Selected Cost
Pregnancy Test (Serum)	Y	3.00	1.00												3,990.00	1,330.00
Pregnancy Test (Urine)	Y	6.00													600.00	100.00
PCR Test for COVID	Y	7.00	1.00												4,550.00	650.00
Antigen Test for COVID	Y	7.00	1.00												3,640.00	520.00
Total															12,780.00	

Patient Cost For Standard Items

	Screening	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Early Termination	Unscheduled	Total
Costs Charged with Overhead	40,112.98	12,032.00	12,032.00	34,614.00	14,038.00	34,059.00	38,576.49	14,038.00	29,205.00	34,966.49	30,805.00	30,805.00	328,537.95		328,537.95
Overhead at 25%	10,028.24	3,008.00	3,008.00	8,653.50	3,509.50	8,514.75	9,644.12	3,509.50	7,301.25	8,741.62	7,701.25	7,701.25	82,134.49		82,134.49
Selected Cost Per Visit	50,141.22	15,040.00	15,040.00	43,267.50	17,547.50	42,573.75	48,220.61	17,547.50	36,506.25	43,708.11	38,506.25	38,506.25	410,672.44		410,672.44

Patient Cost For Conditional Items

	Screening	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Early Termination	Unscheduled	Total
Costs Charged with Overhead	2,500.00			2,600.00		1,270.00	2,600.00		1,270.00		1,270.00			12,780.00
Overhead at 25%	625.00			650.00		317.50	650.00		317.50		317.50			3,195.00
Selected Cost Per Visit	3,125.00			3,250.00		1,587.50	3,250.00		1,587.50		1,587.50			15,975.00

Overall Patient Cost

	Screening	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Treatment	Early Termination	Unscheduled	Total
Costs Charged with Overhead	42,612.98	12,032.00	12,032.00	37,214.00	14,038.00	35,329.00	41,176.49	14,038.00	30,475.00	36,236.49	30,805.00	30,805.00	341,317.95	
Overhead at 25%	10,653.24	3,008.00	3,008.00	9,303.50	3,509.50	8,832.25	10,294.12	3,509.50	7,618.75	9,059.12	7,701.25	7,701.25	85,329.49	
Selected Cost Per Visit	53,266.22	15,040.00	15,040.00	46,517.50	17,547.50	44,161.25	51,470.61	17,547.50	38,093.75	45,295.61	38,506.25	38,506.25	426,647.44	



Site Level Other Direct Costs

Name	OH?	Selected Cost	Comment
Study Set-Up	N	30,000.00	Paid upon site activation
Archiving Fee	N	225,000.00	Paid upon Study close-out
Participant travel and meal reimbursements:	N	Actual costs	Actual costs up to 1500 INR per visit. Costs above this amount require

SCHEDULE III DESCRIPTION OF PERSONAL DATA PROCESSING

1. Introduction

- (i) INSTITUTION and INVESTIGATOR shall process Personal Data as determined in this Schedule III on behalf of ERGOMED (the Sponsor's processor) as ERGOMED's sub-processors. Nothing in this Agreement derogates or prevents the INSTITUTION or INVESTIGATOR to keep Clinical Trial and medical documentation as prescribed by the applicable mandatory Regulations, nor excludes their obligations and responsibilities as Controllers when they Process Personal Data of their employees, contractors, sub-contractors or Clinical Trial Subjects.
- (ii) INSTITUTION and INVESTIGATOR should comply with the requirements for collection, storage and processing under the Data Protection Laws.
- (iii) The technical and organizational measures regarding the security of the Personal Data Processing are specified in Schedule IV herein.

2. Categories of Data Subjects

The Personal Data concerns the following categories of Data Subjects:

- INVESTIGATOR and INVESTIGATOR's team;
- Clinical Trial Subjects.

3. The duration of the Processing (retention period)

The processing activities based on this Agreement shall be performed during the term of the Agreement <if possible state exact number of years here>. Retention period for all Categories of Personal Data is defined by the Sponsor. It starts from the Effective Date of this Agreement and last for _____ years after closure of the Clinical Trial. <Please insert the period as under the Article 2.23.> (PLEASE VERIFY THIS SERIAL NUMBER, IT COULD BE 2.26)

4. The source of Personal Data:

- of the INVESTIGATOR and INVESTIGATOR's team: Data Subject;
- of Clinical Trial Subjects: Data Subject and the INVESTIGATOR;

5. The Recipients of Personal Data of all Categories of Data Subjects:

- the regulatory authority;
- IRB/EC;
- publicly accessible trial registries and databases;
- Sponsor's and ERGOMED's contracted service providers;
- Sponsor's and ERGOMED's Affiliates involved in research, development and commercialization of medical products and their contracted service providers;
- Sponsor's contract partner(s) in case they take over the development and/or commercialization of medical products;
- insurance company, legal and/or medical advisors or consultants engaged by all entities mentioned above.

6. Categories of Personal Data

- a. INVESTIGATOR's and INVESTIGATOR team's: Personal Data is listed in Personal Data information notice.
- b. Clinical Trial Subject:
 - (i) Processing by the INVESTIGATOR and INSTITUTION:
 - surname, first name, patronymic, matronymic and contact details (address, telephone, mobile, fax, e-mail address);
 - health data;
 - other Personal Data needed for the conduct of the Clinical Trial.
 - (ii) Processing by ERGOMED and Sponsor:
 - Personal Data incl. health data –
 - pseudonymised for: ERGOMED and Sponsor
 - full detail when at the investigational site for: assigned ERGOMED's and Sponsor's staff (e.g. monitors, site managers, study physician, auditors) for verification of clinical trial procedures and/or data, without violating the confidentiality of the Clinical Trial Subject.

7. Processing activities

The Personal Data shall be subject to the following Processing activities: collecting, recording, systemizing, accumulating, storing, rectifying (updating, modifying), retrieving, using, transferring (distributing, providing, accessing), blocking, erasing or removing.

8. In accordance with the Article 2.11 of this Agreement, ERGOMED hereby confirms that it has authorised INSTITUTION and INVESTIGATOR, in the course of providing its clinical research organisation services to the Sponsor, to engage subcontractors (“**Sub-processor(s)**”) and to transfer to its Sub-processors, on ERGOMED's behalf, the Personal Data. INSTITUTION and INVESTIGATOR are obliged to beforehand inform ERGOMED of any intended changes concerning the involvement, addition or replacement of Sub-processors, and ERGOMED is entitled to object such Sub-processor. Furthermore, the same Data Protection Laws obligations as imposed in this Agreement on INSTITUTION and INVESTIGATOR by ERGOMED shall be imposed on that Sub-processor by way of a contract and INSTITUTION and INVESTIGATOR are fully responsible for Sub-processor's non-compliance with the Data Protection Laws.

9. INSTITUTION and INVESTIGATOR warrants and represents that they shall:

- (i) Process the Personal Data only in accordance with the Data Protection Laws and ERGOMED's written instructions as specified in this Agreement or as may be issued in writing by ERGOMED from time to time, unless required to do so by European Union or European Union Member State law to which INSTITUTION and INVESTIGATOR and/or the INVESTIGATOR's team and/or the Clinical Trial Subject is subject; in such a case, INSTITUTION and INVESTIGATOR shall inform ERGOMED of that additional legal requirement before Processing, unless that law prohibits such information on important grounds of public interest. Should INSTITUTION and INVESTIGATOR be unable for any reason to ensure its compliance with any duties stipulated by the Data Protection Laws, this Agreement or ERGOMED's instructions, INSTITUTION and INVESTIGATOR shall immediately notify ERGOMED, who may suspend the Processing of the Personal Data.
- (ii) promptly, and in any case no later than 24 (twenty-four) hours after discovering or suspecting a Personal Data Breach, (i) notify responsible ERGOMED's monitor and data protection officer at DPO@ergomedplc.com of such Personal Data Breach; (ii) investigate

the Personal Data Breach and provide responsible ERGOMED's monitor with detailed information about the Personal Data Breach; and (iii) take reasonable steps to mitigate the effects and to minimize any damage resulting from the Personal Data Breach. If INSTITUTION and INVESTIGATOR are unable to provide the notice within 24 (twenty-four) hours, they shall provide ERGOMED with reasons for the delay. Where necessary, INSTITUTION and INVESTIGATOR shall assist ERGOMED or Sponsor when notifying relevant party about Personal Data Breach and/or when communicating to the data subjects.

- (iii) immediately inform ERGOMED if, in INSTITUTION's and/or INVESTIGATOR's opinion, ERGOMED's instructions violate any Data Protection Laws or other Regulations. INSTITUTION and INVESTIGATOR shall be entitled to suspend and refuse the execution of ERGOMED's instructions that are in violation of the Data Protection Laws or other regulation until ERGOMED confirms that there is no such violation or modifies its instructions.
- (iv) provide ERGOMED with all necessary materials, documents, assessments and other information to enable ERGOMED to confirm that INSTITUTION and INVESTIGATOR have complied with their obligations under the Data Protection Laws and this Agreement. Moreover, where necessary, INSTITUTION and INVESTIGATOR shall help Sponsor in conducting data privacy impact assessment as well as prior consultation procedure, or any other activity required by EGROMED or Sponsor in order to demonstrate their compliance with GDPR. INSTITUTION and INVESTIGATOR shall allow for and contribute to GDPR audits to ensure compliance with the Data Protection Laws. GDPR audits shall be carried out during customary business hours following a prior announcement of 7 (seven) working days.
- (v) notify ERGOMED promptly and in any event within 1 (one) working day of receiving any communication, complaint, inquiry, or request from any third party, including a regulatory authority or a Data Subject, relating to the Personal Data Processing by INSTITUTION and INVESTIGATOR. INSTITUTION and INVESTIGATOR shall not respond to that request except on the documented instructions of ERGOMED or Sponsor or as required by applicable Regulations to which the INSTITUTION and INVESTIGATOR are subject, in which case INSTITUTION and INVESTIGATOR shall to the extent permitted by applicable Regulations inform ERGOMED.
- (vi) to comply with their obligations under the Data Protection Laws. In that light, INSTITUTION and INVESTIGATOR shall take appropriate technical and organisational security measures to safeguard the Personal Data against unauthorised or unlawful access, modification and against accidental loss or destruction of, or damage to the Personal Data, unauthorised transfer or other unauthorised Processing of any Personal Data or any other misuse of the Personal Data, as specified in Schedule IV herein.
- (vii) Ensure that all persons engaged by INSTITUTION and INVESTIGATOR and its employees respect confidentiality obligation defined in Article 7.

In case of earlier termination of this Agreement or its regular expiry, INSTITUTION and INVESTIGATOR have to retain all Personal Data that is subject of this Agreement (ISF and medical records related to the Clinical Trial and Clinical Trial Subjects entered into CRF), as defined by Sponsor and required by Regulations, only to the extent and for such period as required by applicable Regulations.

INSTITUTION and INVESTIGATOR shall ensure the confidentiality of all such Personal Data and shall ensure that such Personal Data is only retained as necessary for the purpose(s) specified

by Sponsor requiring its storage and for no other purpose. This Personal Data has to be archived at the site as per applicable regulatory requirements and in line with Sponsor's agreement.

10. INSTITUTION and INVESTIGATOR shall only transfer the Personal Data from any jurisdiction to any other jurisdiction (the European Economic Area ("EEA") constituting a single jurisdiction for this purpose) as necessary to provide the Services under this Agreement or where otherwise instructed by ERGOMED, unless required to do so by law to which INSTITUTION and INVESTIGATOR are subject; in such a case INSTITUTION and/or INVESTIGATOR shall inform ERGOMED of that legal requirement before Processing, unless that law prohibits such information on important grounds of public interest.
11. INSTITUTION and INVESTIGATOR shall indemnify ERGOMED for any damage suffered by ERGOMED and/or any affiliate of ERGOMED as a consequence of or ensuing from breach by the INSTITUTION and INVESTIGATOR and/or their Sub-processors to perform the obligations under this Agreement relating to data protection. For the purposes of this Article, damage shall mean: (i) fines and other penalties imposed by a supervisory authority or other government agency; (ii) compensation claimed by third parties and; (iii) reasonable costs connected with the execution of this Article.

SCHEDULE IV TECHNICAL AND ORGANIZATIONAL SECURITY MEASURES

1. *Certification*- Obtain and implement the IS/ISO//IEC 27001 standard. If the INSTITUTION does not have an IS/ISO//IEC 27001 certification, a comprehensive information security policy may be adopted by the INSTITUTION and subsequently approved by ERGOMED or the Sponsor.
2. *Physical security and access control* - Rights to access and operate the automatic data processing system shall be available only to INSTITUTION's employees, INVESTIGATOR and members of INVESTIGATOR's team who shall be trained in handling of the Personal Data and who shall directly handle such Personal Data. Such persons shall only have access to the Personal Data corresponding to their respective authorisations, which shall be granted solely to such persons. INSTITUTION and INVESTIGATOR shall ensure that the IT systems utilized for the Processing of the Personal Data only allow authorised users access to the data limited to their individual authorisation rights.
3. *Confidentiality* - INSTITUTION and INVESTIGATOR shall at all times keep confidential all Personal Data it Processes pursuant to this Agreement. INSTITUTION and INVESTIGATOR may disclose the Personal Data to its employees, members of INVESTIGATOR's team, officers, representatives or advisers who need to know such information for the purposes of carrying out its obligations under this Agreement provided that such employees, officers, representatives or advisers are required to maintain the confidentiality of the Personal Data in accordance with the terms of this Agreement.
4. *Availability control* - INSTITUTION and INVESTIGATOR shall ensure that the Personal Data cannot be unintentionally lost or destroyed. Without limitation to the foregoing, INSTITUTION and INVESTIGATOR shall implement an antivirus protection system for all equipment used in the Processing of the Personal Data and a data security backup system.
5. *Transfer control* – INSTITUTION and INVESTIGATOR shall ensure that during any transfer of the Personal Data it cannot be read, copied, modified or deleted without authorisation.
6. *Input control* – INSTITUTION and INVESTIGATOR shall implement a system to log who enters the Personal Data into the system used in the Processing of the Personal Data and by whom the Personal Data is removed from such systems.
7. *Separation of data processing for different purposes* – INSTITUTION and INVESTIGATOR shall ensure that any Personal Data collected for different purposes is processed separately.



Sri Devaraj Urs Academy of Higher Education and Research

Comprising Sri Devaraj Urs Medical College

(A Deemed to be University)

Research and Development Cell

Central Ethics Committee Re-registered under CDSCO -Registration No. ECR/425/Ins/KA/2013/RR-20 dated 29.4.2020

No. SDUAHER/KLR/KLR/R&D/169/2024-25

Date: 10.03.2025

From:

The Director
Research & Development Cell
SDUAHER

To:

The Registrar
SDUAHER

Respected Sir,

Sub: Submission of Statement of Expenditure for National Scientific Conclave on Interdisciplinary Research conducted on 4th & 5th February 2025.

With reference to above subject mentioned, I thank you for the invaluable support you extended for the conduct of National Scientific Conclave on Interdisciplinary Research on 4th and 5th February 2025. Herewith I am submitting the Statement of Expenditure of the same also enclosed copy of Event report.

Kindly accept and oblige and looking forward for the same kind of support for the conduct of National Scientific Conclave 2026

Prepared By

Soumya N
Dr. Soumya N
Dr. Deckshitha
Members of R&D Cell
SDUAHER

Verified by

R. Venkateswarlu Raavi
Dr. Venkateswarlu Raavi 10/3/25
Deputy Co-Ordinator
R&D Cell, SDUAHER

Deputy-Coordinator
Department of Research and Innovation
Sri Devaraj Urs Academy of
Higher Education & Research
Tumakuru, Kolar, Karnataka-563103

Approved by

Kalyani R
Dr. Kalyani R 10/03/25
Director
R&D Cell, SDUAHER

Prof. Dr. Kalyani . R.
MD(Path), Ph.D, FAMS, FICP, FIAMS, FIMSA, FKSTA
Director
Research and Development Cell, SDUAHER
Professor & Former Head
Dept. of Pathology, SDUMC



Sri Devaraj Urs Academy of Higher Education and Research

Comprising Sri Devaraj Urs Medical College

(A Deemed to be University)

Research and Development Cell

Central Ethics Committee Re-registered under CDSCO -Registration No. ECR/425/Inst/KA/2013/RR-20 dated 28.4.2020

No. SDUAHER/KLR/KLR/R&D/167/2024-25

Date: 10.03.2025

National Scientific Conclave on Interdisciplinary Research conducted on 4th & 5th February 2025

Utilization certificate

Certified that out of Rs. 25,000/- sanctioned dated: 23rd January 2025 with email reference by Karnataka Science and Technology Academy(KSTA), Bangalore towards financial assistance for the conduct of National Scientific Conclave on Interdisciplinary Research on 4th & 5th February 2025, an amount of Rs.25,000/- was utilized for the purpose for which it was sanctioned leaving the balance of Rs.0/-

Kalyani R
10/03/25
Dr. Kalyani R
Director
R&D Cell, SDUAHER
Organizing Chairperson

Prof. Dr. Kalyani . R.
MD(Path), Ph.D. FAMS, FICP, FIAMS, FIMSA, FKSTA
Director
Research and Development Cell, SDUAHER
Professor & Former Head
Dept. of Pathology, SDUMC



Sri Devaraj Urs Academy of Higher Education and Research

Comprising Sri Devaraj Urs Medical College

(A Deemed to be University)

Research and Development Cell

Central Ethics Committee Re-registered under CDSCO -Registration No. ECR/425/Inst/KA/2013/RR-20 dated 28.4.2020

No. SDUAHER/KLR/KLR/R&D/163/2024-25

Date: 10.03.2025

National Scientific Conclave on Interdisciplinary Research Revolutionizing Health Outcomes through collaborative efforts across Basic, Allied Health and Medical Sciences" on 4th & 5th February 2025

UTILIZATION REPORT		
RECEIVED AMOUNT		
S.NO.	PARTICULARS	AMOUNT in Rs
1	KSTA	25,000
2	Dr. Jagdale sir	20,000
3	Retra	4,000
4	Winmedicare	8,000
5	REGISTRATION AMOUNT	128150
TOTAL		1,85,150
NOTE : YET TO RECEIVE		
1	MERT	25,000
2	CSIR	25,000
TOTAL		50,000
SDUAHER (SANCTIONED AMOUNT) : Rs.10,00,000/-		
EXPENDITURE		
S.NO.	PARTICULARS	AMOUNT in Rs
1	FOOD	247340
2	TA/DA and HONORORIUM	98244
3	STATIONARY	183763
4	MOMENTOS (INCLUDING CHIEF GUEST)	22671
5	PRIZE MONEY	21000
6	DECORATION	63500
7	VIDEO STREAMING & PHOTOGRAPHY	46030
8	MISCELLANEOUS	38096
TOTAL		720644

Prepared By
Soumya D.
Dr. Soumya N
Dr. Deekshitha
Members of R&D Cell
SDUAHER

Verified by
R. Venkateswarlu Raavi
Dr. Venkateswarlu Raavi 10/3/25
Deputy Co- Ordinator
R&D Cell, SDUAHER
Deputy Coordinator
Department of Research and Innovation

Approved by
Kalyani R.
Dr. Kalyani R 10/03/25
Director
R&D Cell, SDUAHER
Prof. Dr. Kalyani . R.

Sri Devaraj Urs Academy of Higher Education & Research
Ph No: +91-9448402775 (Extn. 480) Email ID: dir-research@sduahe.ac.in
Director
Research and Development Cell, SDUAHER



MEDICAL EDUCATION & RESEARCH TRUST (R)

KARNATAKA

API BHAVANA, # 16/F, Millers Tank Bund Road, Vasanthanagar, Bengaluru - 560 052.

Ph: 2235 3525 / 4149 4070, E-mail : info@mert.org.in, Website: www.mert.org.in

Founder Chairman :
Late Dr. K.S. Shadaksharappa

Emeritus Chairman :
Dr. M. Maiya
☎ : 2660 7447 (R), 98450 41731

Chairman :
Dr. P. Chandrasekhara
Mo.: 95356 78965

Vice Chairman :
Dr. S. T. Yavagal
Mo.: 98450 05350

Hon. Secretary :
Dr. V. Channaraya
Mo.: 93412 34049

Hon. Joint Secretary :
Dr. Latha Venkataraman
Mo.: 98450 34547

Hon. Treasurer :
Dr. K. Ravi
Mo.: 98451 28212

Trustee's
Dr. M. Maiya
Dr. C. Munichoodappa
Dr. S.T. Yavagal
Dr. T. Prabhu
Dr. P. Mohan Rao
Dr. I.B. Vijayalakshmi
Dr. A.C. Sreeram
Dr. P. Chandrasekhara
Dr. V. Channaraya
Dr. S. M. Sureswaraiah
Dr. K. S. S. Bhat
Dr. K. Ravi
Dr. Latha Venkataraman
Dr. Asha Benakappa

Rotating Trustees :
Dr. M. Narayanaswamy (2026)
Dr. B. S. Nagaraja (2025)
Dr. B. J. Subhash Chandra (2025)
Dr. Shubha Badami (2025)

Institutional Trustees :
API Chairman
IMA President

2024-2025
Ref. No.:

Date : 25.11.2024

Dr.Kalyani.R
Organising Chairperson
Director
Research & Development Cell
SDUAHER, Kolar

Dear Dr. Kalyani.R

Thank you for your letter dt: 29.10.2024 along Programme for Financial Assistance to conduct Conference on **"National Scientific Conclave on Interdisciplinary Research"**. We are glad to Sanction Rs.25,000/- (Rupees Twenty Five thousand Only) towards your Conference. It is Necessary that the name and Logo of **"MEDICAL EDUCATION & RESEARCH TRUST" KARNATAKA** should be mentioned in your Program as sponsorer. I request you to Send the Program brochure and Photos. We will be releasing the said amount after receiving your program report. In the covering letter please mention the cheque Pay name.

Thanking you,

Yours sincerely,

(Dr.P.Chandrasekhara)
Chairman


(Dr.V.Channaraya)
Hon.Secretary



Director Research <dir.research@sduahe.ac.in>

Request for Grant in aid for National Scientific Conclave on 4th & 5th February 2025

Kstacademy <ksta.gok@gmail.com>

Thu, Jan 23, 2025 at 4:33 PM

To: Director Research <dir.research@sduahe.ac.in>

Dear Madam,

Greetings from Karnataka Science and Technology Academy (KSTA), DST, GoK.

Thank you for submitting the proposal for financial support to organize the National Scientific Conclave on Interdisciplinary Research, scheduled for the 4th and 5th of February 2025. In this regard, I am pleased to inform you that KSTA will be transferring Rs. 25,000/- for the proposed conclave. I kindly request you to kindly submit the Utilization Certificate (UC) and Statement of Expenditure (SE) within a month after the completion of the event.

With regards,

Dr A M Ramesh
CEO, KSTA

[Quoted text hidden]



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION &
RESEARCH
SRI DEVARAJ URS MEDICAL COLLEGE
Tamaka, Kolar
FORENSIC MEDICINE AND TOXICOLOGY



NO: SDUMC/KLR/FM/ 23/2025-26

Date: 12/05/2025

From,
Dr. Ajay Kumar T S,
Professor and Head,
Department of Forensic Medicine and Toxicology,
SDUMC, Kolar - 563103

To,
The Director, Research and Development Cell,
SDUAHER,
Tamaka, Kolar – 563103

Respected Sir,

(Through, The Principal, SDUMC, Kolar)

Subject: Submission of Revenue Generated from External Students – Internships,
(June 2024 – May 2025) - reg.

I am hereby submitting the consolidated report on the revenue generated from external students through internships conducted between June 2024 and May 2025.

SL. No	Name of College	Number of Trainees	Period	Amount Generated (In Rs.)
1	Department of Forensic Science, School of Science, JAIN (Deemed to be University) J.C.Road, Bangalore-27	05	18-09-2024 to 18-10-2024	10,000/-
2	Department of Forensic Science, School of Science, JAIN (Deemed to be University) J.C.Road, Bangalore-27	03	03-03-2025 to 02-04-2025	6000/-
3	SEA College of Science, Commerce and Arts Ektha Nagar, Virgonagar post, K.R.Puram, Bangalore-560045	06	01-04-2025 to 30-04-2025	12,000/-

Thank you,

Yours Sincerely,
12/5/25
Dr. Ajay Kumar. T.S.
Professor & Head,
Dept. of Forensic Medicine & Toxicology,
Sri Devaraj Urs Medical College,
Tamaka, Kolar - 563 103.



R. L Jalappa College of Physiotherapy

Sri Devaraj Urs Academy of Higher Education and Research

(A deemed to be University declared under section 3 of the UGC Act 1956)



SDUAHER/PT/ 76 /2024-25

Date: 9/5/2025

To,
Research & Development Cell,
Coordinator
SDUAHER

Respected Sir,

Through Proper channel

Subject-Submitting NAAC criterion 3 details. - Reg

With reference to above subject, we are submitting the NAAC criterion 3 (data on revenue generated from external students project collaboration, external student internship/workshop/ conference). Kindly accept and do the needful.

Thanking you

Yours sincerely

Prof. Dr. Senthil Kumar E
HOD. Dept. of Physiotherapy
SDUAHER.

Prof. Dr. Senthil Kumar E
Department of Physiotherapy
SDUAHER

RLCOPT

Post-box No 62, Tamaka Kolar -563103 Karnataka, India
www.sduaher.ac.in Email: rlcopt@sduaher.ac.in

Revenue Generated from External Students Internship

Sl.No.	Students Name	Months of Internship	Amount	Supporting documents
1.	Pranav Pradeep	6 Months	Rs. 12,000	<u>Annexure 1</u>
2.	Inchara	6 Months	Rs. 12,000	
3.	Monisha	3 Months	Rs. 6,000	
	Total:		Rs. 30,000	

Revenue Generated from Workshop/ Conference

Sl.No.	Event	Date	Amount	Supporting documents
1.	Workshop: Physiotherapy in Critical Care	24 th & 25 th January 2025	Rs. 37,500	<u>Annexure 2</u>
2.	International Conference: 1 st International Conference on Physiotherapy Education and Research 2025	6 th , 7 th & 8 th March 2025	Rs. 10,06,050	<u>Annexure 3</u>
	Total:		Rs.10,43,550	

Total Revenue Generated

Sl.No.	Source of Revenue	Amount
1.	Workshop/ Conference	Rs. 10,43,550
2.	External Students Internship	Rs. 30,000
	Total:	Rs. 10,73,550

Prepared by
Dr. Saniksha Revandikar

Dr. Saniksha Sudhir Revandikar MPT (Ph.D)
Assistant Professor &
Consultant Physiotherapist
Emp. ID C 3096
RLJCOPT, SDUAHER

HOD Signature
Dr. Saniksha Revandikar
Head of Department
Department of Physiotherapy
R. L. Jalappa College of Physiotherapy
SDUAHER

RLCOPT

Post-box No 62, Tamaka Kolar -563103 Karnataka, India
www.sduaher.ac.in Email : rlcopt@sduaher.ac.in



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No.SDUAHER/KLR/ADMN/ 3731/2024-25

Date: 10th Feb. 2025

NOTE


Sub: Permission to do Internship at CBMG, SDUAHER.

Ref: E-mail from the HoD, Dept. of Life Sciences, SBMJC, KGF,
dated 8th Feb. 2025,

With reference to the above, the following students of the Department of Life Sciences, III Year B.Sc. Biotechnology, SBMJC, KGF are permitted to undertake Internship at the Department of Cell Biology and Molecular Genetics, SDUAHER, Kolar for a duration of two weeks from 11.02.2025 to 25-02-2025.

1. Ms. Deepthi, R.
2. Ms Vidhyasree R C,
3. Ms Griselda P,
4. Ms Linda J
5. Ms.Blessy Mayor Maneksha C

This is for your information and further needful action.


10/2/2025

Registrar

Sri Devaraj Urs Academy of Higher
Education and Research
To, Tamaka, Kolar - 563 103.

Concerned students.



Chief Administrative Officer
Chief Administrative Officer
Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar-563103

Copy to:

1. The P.A. to V.C., SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The F.O., SDUAHER.
4. The HoD, Department of CB&MG, SDUAHER.
5. O/c.



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0005059	Date :	12/02/2025
Name :	VIDHYASREE R C (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	1,000.00	
Total Amount Paid :		1,000.00	
Amount In Words :	ONE THOUSAND ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	12/02/2025
Bank	State Bank of India		
Branch	Ah&Bs 75591	DD No.	504360505289

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563101.



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0005061	Date :	12/02/2025
Name :	LINDA J (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	1,000.00	
Total Amount Paid :		1,000.00	
Amount In Words :	ONE THOUSAND ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	12/02/2025
Bank	State Bank of India		
Branch	Ah&Bs 75591	DD No.	504360505289

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563101



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0005060	Date :	12/02/2025
Name :	GRISELDA P (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	1,000.00	
Total Amount Paid :		1,000.00	
Amount In Words :	ONE THOUSAND ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	12/02/2025
Bank	State Bank of India		
Branch	Ah&Bs 75591	DD No.	504360505289

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0005062	Date :	12/02/2025
Name :	BLESSY MAYOR MANEKSHA C (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	1,000.00	
Total Amount Paid :		1,000.00	
Amount In Words :	ONE THOUSAND ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	12/02/2025
Bank	State Bank of India		
Branch	Ah&Bs 75591	DD No.	504360505289

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education
Tamaka, Kolar, Karnataka



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0005058	Date :	12/02/2025
Name :	DEEPTHI R (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	1,000.00	
Total Amount Paid :		1,000.00	
Amount In Words :	ONE THOUSAND ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	12/02/2025
Bank	State Bank of India		
Branch	Ah&Bs 75591	DD No.	504360505289

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/3905/2024-25

Date: 11.03.2025

NOTE

Sub: Permission to do Internship in the Dept. of CBMG,
SDUAHER-reg.

Ref. Letter from the Dr. G. Hema, Chairperson BOS/BOE Dept. of
Studies in Biotechnology, Maharani Cluster University,
Bangalore, dated.06.03.2025.

With reference to the above the following external students of 3rd year, 6th
semester B.Sc., Biotechnology, Maharani Cluster University, Bengaluru are
permitted to do Internship in the Dept. of Cell Biology & Molecular Genetics
(CBMG) SDUAHER.

S.I No	Name	Reg. No	Contact No	Period of Internship
1.	Sandhya	U20AU22S0228	7022942582	15 Days
2.	Haritha	U20AU22S0341	7899415005	
3.	Deepthi	U20AU22S0381	8431744326	

This is for your information and further needful action.

Registrar
Registrar

Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar - 563 103.

Dr. G. Hema, M.Sc., Ph.D.
Chairperson BOS/BOE
Dept. of Studies in Biotechnology,
Maharani Cluster University,
Bangaluru-560001

Copy to:

1. PA to VC, SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The Finance Officer, SDUAHER.
4. The Asst. Professor & I/c HoD of CBMG, SDUAHER.
5. Concerned Students, Maharani Cluster University, Bangaluru.
6. O/c.

Chief Administrative Officer

Chief Administrative Officer
Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar-563103

*Kiranmayee is mentor
for these three students*

**DEPARTMENT OF BIOTECHNOLOGY
 MAHARANI'S SCIENCE COLLEGE FOR WOMEN, MAHARANI CLUSTER UNIVERSITY
 PALACE ROAD, BANGALORE-01.**

Date: 06.03.2025

From
Dr.G.Hema
 Chairperson and Professor,
 Department of Biotechnology,
 School of Sciences,
 Maharani Cluster University,
 Palace Road, Bangalore
 9986190921.

To: CAO / Registrar.

1620 Consider the request of
 07/03/25 Internship of 15 days.

As per our policy,
 Students to be posted in
 the CBMG Dept for 15 days.

To,
R.L. Jalappa Hospital & Research Centre
 Tamaka, Karnataka-563 101.

Sub: Request for student internship / training program

Dear Sir/Madam,

Greetings!

With respect to the above mentioned student, I request you to please allow our final year B.Sc., Biotechnology Students (3 students), to undertake internship (for a period of 15 days), at your esteemed organization. This will allow them to fulfill the requirement of internship as per their curriculum. It will also be great opportunity of practical learning and scientific exposure for our students. We will be extremely obliged if you can provide this opportunity to our students. Please let me know more details regarding the same.

List of students attending


Name of the students	Register Number	Contact Number
Sandhya	U20AU22S0228	7022942582
Haritha	U20AU22S0341	7899415005
Deepthi	U20AU22S0381	8431744326

Thanking you,

Yours sincerely,

Hema G
Dr. G. HEMA, M.Sc., Ph.D.
 Chairperson BOS/BOE

Department of Studies in Biotechnology
 Maharani Cluster University
 Palace Road, Bengaluru - 560 001.



Students of 3rd Year 6th Sem
 B.Sc., Biotechnology
 Maharani Cluster University.

Approved as per the policy



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No,9-36/2006-U,3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka, Kolar, Karnataka, India-563101

Receipt

Receipt No :	2024-25/MF/0005861	Date :	17/03/2025
Name :	SANDHYA ()	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	1,000.00	
Total Amount Paid :	1,000.00		
Amount In Words :	ONE THOUSAND ONLY		
Additional Comment	PAID TOWARDS INTERSHIP FOR 15 DAYS		
Details of Payment			
Payment Mode :	NEFT	DateTime :	17/03/2025
Bank	State Bank of India		
Branch	Sdumc 2124	DD No.	634783135083

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar-563103



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-J.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka, Kolar, Karnataka, India-563101

Receipt

Receipt No :	2024-25/MF/0005862	Date :	17/03/2025
Name :	HARITHA ()	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	1,000.00	
Total Amount Paid :		1,000.00	
Amount In Words :	ONE THOUSAND ONLY		
Additional Comment	PAID TOWARDS INTERSHIP FOR 15 DAYS		
Details of Payment			
Payment Mode :	NEFT	DateTime :	17/03/2025
Bank	State Bank of India		
Branch	Sdumc 2124	DD No.	634783135083

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar-563103



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9/36/2006-U,3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka, Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0005863	Date :	17/03/2025
Name :	DEEPTHI ()	Roll No :	N/A
Program :		Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	1,000.00	
Total Amount Paid :		1,000.00	
Amount In Words :	ONE THOUSAND ONLY		
Additional Comment	PAID TOWARDS INTERSHIP FOR 15 DAYS		
Details of Payment			
Payment Mode :	NEFT	DateTime :	17/03/2025
Bank	State Bank of India		
Branch	Sdumc 2124	DD No.	634783135083

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar-563103



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/3927/2024-25

Date: 27.01.2025

NOTE

Sub: Permission for Ms. Keerthana S K. B.Tech, Biotechnology, Sir MVIT, Bangalore, to undertake an Internship at the Department of CB&MG, SDUAHER.-reg.

Ref. Letter from Keerthana S K. B.Tech, Biotechnology, Sir MVIT, Bangalore.

With reference to above, Ms. Keerthana S K. B.Tech, Department of Biotechnology, Sir MVIT, Bangalore, is granted permission to undertake an Internship at the Dept. of CB&MG, SDUAHER for a duration of two months from 27.01.2025 to 27.03.2025.

This is for your information and further needful action.

Registrar

Registrar
Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar - 563 103.

Chief Administrative Officer

Chief Administrative Officer
Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar-563103

To,

1. The Prof & HoD,
Dept. of CBMG,
SDUAHER, Kolar.
2. Ms. Keerthana S K.
B.Tech
Sir MVIT,
Bangalore,

Copy to:

1. The Dean, FAH&BS, SDUAHER.
2. The Finance Officer, SDUAHER.
3. O/c.

No: SDUAHER / KUR / CBMG / 07 / 2024 - 25 Kolar
Jan 17, 2025

TO
The Registrar
SDUAHER
Kolar



TO CAO (Registrar)
Consider the request as
per our Internship policy
(Ref NAAE 3.5.2)

From
Dr. Kiranmayee P.
CBMG, SDUAHER, Kolar.

[Handwritten signature]
Dean

Faculty of Allied Health Sciences
Sri Devaraj Urs Academy of
Higher Education & Research
Tumaka, Kolar 563 101.

Through proper channel

Sub:- Request to permit B.Tech student to do internship in CBMG dept

Sir,

Ms. Keerthana S.K., from Kolar, wants to do a two month internship in CBMG department. She is interested in to work on biomolecules from plants and microorganisms and check their efficacy on multi drug resistant bacteria. She will abide the rules of our internship policy and she is ready to pay if any chemicals are involved in the project.


Since my work is also has relevance to her interest, I would like to guide her during her internship stay in CBMG dept.

I humbly request you to give permission to Ms. Keerthana to do her internship under my guidance in CBMG.

I am enclosing the request letter from Ms. Keerthana.

Sincerely

[Handwritten signature]
Head of Dept.
Cell Biology & Molecular Genetics
SDUAHER - Kolar



TO CAO for
approval

[Handwritten signature]
17/1/2025

[Handwritten signature]

Not signed



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0004903	Date :	27/01/2025
Name :	KEERTHANA S K ()	Roll No :	N/A
Program :		Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	4,000.00	
Total Amount Paid :		4,000.00	
Amount In Words :	FOUR THOUSAND ONLY		
Additional Comment	INTERNSHIP FOR 2 MONTHS		
Details of Payment			
Payment Mode :	NEFT	DateTime :	27/01/2025
Bank	State Bank of India		
Branch	Sdumc2124	DD No.	923099196988

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 105.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduahe.ac.in / office@sduahe.ac.in. Website: www.sduahe.ac.in

No. SDUAHER/KLR/ADMIN/ 3926/2024-25

Date: 27.01.2025

NOTE

Sub: Permission for Ms. Pavana J, 3rd Semester, Biothechnology, JSS Science and Technology University, Mysore to undertake an Internship and project at the Department of CB&MG, SDUAHER.

Ref. Letter from Pavana J, M.Tech, 3rd Sem, Biotechnology, JSS Science and Technology University, Mysore.

With reference to above, Ms. Pavana.J, Student of 3rd Semester, M.Tech, Department of Biotechnology, JSS Science and Technology University, Mysuru, is granted permission to undertake an Internship and project at the Dept. of CB&MG, SDUAHER for a duration of two months from 27.01.2025 to 27.03.2025.

This is for your information and further needful action.

Registrar

Registrar

Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar - 563 103.

Chief Administrative Officer


Chief Administrative Officer
Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar-563103

To,

1. The Prof & HoD,
Dept. of CBMG,
SDUAHER, Kolar.
2. Ms. Pavana.J
Student of 3rd Sem, M.Tech
JSS Science and Technology University,
Mysuru,

Copy to:

1. The Dean, FAH&BS, SDUAHER.
2. The Finance Officer, SDUAHER.
3. O/c.



20th Jan 2025

From
Pavana, J


M.Tech, 3rd sem, Biotechnology,
Department of Biotechnology,
JSS Science and Technology University,
Mysore.

To: I/C HOD, CBME

Through: CAO (Registrar)

To,
The Registrar
SDUMC,
Kolar,

Kindly permit the student
Ms Pavana, J for Internship
as per our Internship policy.
(2 months - Internship)



Dear Sir,

Dean
Faculty of Allied Health Sciences
Sri Devaraj Urs Academy of
Higher Education & Research
Tumakuru, Kolar-563 101

Sub: Requisition for accommodate to Internship and
Project.

I Pavana J currently in 3rd semester, post
graduate M.Tech program I would like to undertake
an internship and project at ~~Microbiology~~ ^{Genetic} Lab
at your prestigious institute for a duration of
10 months.

Yours Sincerely,

Pavana, J

Phone No:- 8884388844
9845694132

~~Approved~~
put up
JSS

To CAO for needed

~~Signature~~
20/01/2025

23/01/2025



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka, Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0004902	Date :	27/01/2025
Name :	PAVANA J (M.TECH)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	4,000.00	
Total Amount Paid :		4,000.00	
Amount In Words :		FOUR THOUSAND ONLY	
Additional Comment		PAID TOWARDS INTERNSHIP FEE FOR 2 MONTHS.	
Details of Payment			
Payment Mode :	NEFT	DateTime :	27/01/2025
Bank	State Bank of India		
Branch	Sdumc 2124	DD No.	789535468204

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/706/2024-25

Date: 25-05-2024

NOTE

Sub: Permission to start internship for B.Sc. Women's College students of Kolar-reg.

Ref.Letter No: SDUAHER/KLR/CBMG/128/2024-25 dated 21-05-2024 from Dr. Kiranmayee.P, Asst.Prof. of CBMG & I/c HoD of CBMG, SDUAHER.

With reference to above letter, permission has been granted by the Academy to undergo Internship in Dept. of CBMG under FAH&BS, SDUAHER from B.Sc. Women's College students of Kolar for 90 hours (6 Biotechnology students). The following students' names are hereunder.

- | | |
|----------------------|--------------------|
| 1. Ms. P.S. Sireesha | 5. Ms. Lavanya C.S |
| 2. Ms. Daniya Kousar | 6. Ms. Afreen Taj |
| 3. Ms. Bhavya B.H | |
| 4. Ms. Dhanyashree S | |

It is intimated that to collect Rs. 2000/- per month from each student to monitor during internship as per internship policy.

This is for your kind information and further needful action.

Rs. 500/- for 7 days of internship

Registrar

Registrar

Sri Devaraj Urs Academy of Higher
Education and Research
Tataka, Kolar - 563 103.

To,

1. Dr. Kiranmayee.P,
Asst.Prof. of CBMG
& I/c HoD of CBMG,
SDUAHER.
2. The concerned students,
B.Sc. Women's College, Kolar.

Copy to:

1. PA to VC, SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The Finance Officer, SDUAHER.
4. O/c.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

- Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/706/2024-25

Date: 25-05-2024

NOTE

Sub: Permission to start internship for B.Sc. Women's College students of Kolar-reg.

Ref.Letter No: SDUAHER/KLR/CBMG/128/2024-25 dated 21-05-2024 from Dr. Kiranmayee.P, Asst.Prof. of CBMG & I/c HoD of CBMG, SDUAHER.

With reference to above letter, permission has been granted by the Academy to undergo Internship in Dept. of CBMG under FAH&BS, SDUAHER from B.Sc. Women's College students of Kolar for 90 hours (6 Biotechnology students). The following students' names are hereunder.

- | | |
|----------------------|--------------------|
| 1. Ms. P.S. Sireesha | 5. Ms. Lavanya C.S |
| 2. Ms. Daniya Kousar | 6. Ms. Afreen Taj |
| 3. Ms. Bhavya B.H | |
| 4. Ms. Dhanyashree S | |

It is intimated that to collect Rs. 2000/- per month from each student to monitor during internship as per internship policy.

This is for your kind information and further needful action.

Rs. 500/- for 7 days of internship.


Registrar

Registrar
Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar - 563 103.

To,

1. Dr. Kiranmayee.P,
Asst.Prof. of CBMG
& I/c HoD of CBMG,
SDUAHER.
2. The concerned students,
B.Sc. Women's College, Kolar.

Copy to:

1. PA to VC, SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The Finance Officer, SDUAHER.
4. O/c.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/70/2024-25

Date: 25-05-2024

NOTE

Sub: Permission to start internship for B.Sc. Women's College students of Kolar-reg.

Ref.Letter No: SDUAHER/KLR/CBMG/128/2024-25 dated 21-05-2024 from Dr. Kiranmayee.P, Asst.Prof. of CBMG & I/c HoD of CBMG, SDUAHER.

With reference to above letter, permission has been granted by the Academy to undergo Internship in Dept. of CBMG under FAH&BS, SDUAHER from B.Sc. Women's College students of Kolar for 90 hours (6 Biotechnology students). The following students' names are hereunder.

- | | |
|----------------------|--------------------|
| 1. Ms. P.S. Sireesha | 5. Ms. Lavanya C.S |
| 2. Ms. Daniya Kousar | 6. Ms. Afreen Taj |
| 3. Ms. Bhavya B.H | |
| 4. Ms. Dhanyashree S | |

It is intimated that to collect Rs. 2000/- per month from each student to monitor during internship as per internship policy.

This is for your kind information and further needful action.

Rs. 500/- for 7 days of internship.

Registrar

Registrar
Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar - 563 103.

To,

1. Dr. Kiranmayee.P,
Asst.Prof. of CBMG
& I/c HoD of CBMG,
SDUAHER.
2. The concerned students,
B.Sc. Women's College, Kolar.

Copy to:

1. PA to VC, SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The Finance Officer, SDUAHER.
4. O/c.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/706/2024-25

Date: 25-05-2024

NOTE

Sub: Permission to start internship for B.Sc. Women's College students of Kolar-reg.

Ref.Letter No: SDUAHER/KLR/CBMG/128/2024-25 dated 21-05-2024
from Dr. Kiranmayee.P, Asst.Prof. of CBMG &
I/c HoD of CBMG, SDUAHER.

With reference to above letter, permission has been granted by the Academy to undergo Internship in Dept. of CBMG under FAH&BS, SDUAHER from B.Sc. Women's College students of Kolar for 90 hours (6 Biotechnology students). The following students' names are hereunder.

- | | |
|----------------------|--------------------|
| 1. Ms. P.S. Sireesha | 5. Ms. Lavanya C.S |
| 2. Ms. Daniya Kousar | 6. Ms. Afreen Taj |
| 3. Ms. Bhavya B.H | |
| 4. Ms. Dhanyashree S | |

It is intimated that to collect Rs. 2000/- per month from each student to monitor during internship as per internship policy.

This is for your kind information and further needful action.

Rs. 500/- for 7 days of internship


Registrar

Registrar
Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar - 563 103.

To,

1. Dr. Kiranmayee.P,
Asst.Prof. of CBMG
& I/c HoD of CBMG,
SDUAHER.
2. The concerned students,
B.Sc. Women's College, Kolar.

Copy to:

1. PA to VC, SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The Finance Officer, SDUAHER.
4. O/c.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH
(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College
[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]
TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/706/2024-25

Date: 25-05-2024

NOTE

Sub: Permission to start internship for B.Sc. Women's College students of Kolar-reg.

Ref.Letter No: SDUAHER/KLR/CBMG/128/2024-25 dated 21-05-2024
from Dr. Kiranmayee.P, Asst.Prof. of CBMG &
I/c HoD of CBMG, SDUAHER.

With reference to above letter, permission has been granted by the Academy to undergo Internship in Dept. of CBMG under FAH&BS, SDUAHER from B.Sc. Women's College students of Kolar for 90 hours (6 Biotechnology students). The following students' names are hereunder.

- | | |
|----------------------|--------------------|
| 1. Ms. P.S. Sireesha | 5. Ms. Lavanya C.S |
| 2. Ms. Daniya Kousar | 6. Ms. Afreen Taj |
| 3. Ms. Bhavya B.H | |
| 4. Ms. Dhanyashree S | |

It is intimated that to collect Rs. 2000/- per month from each student to monitor during internship as per internship policy.

This is for your kind information and further needful action.

Rs. 500/- for 7 days of internship

Registrar

Registrar

Sri Devaraj Urs Academy of Higher
Education and Research
Tumaka, Kolar - 563 103.

To,

1. Dr. Kiranmayee.P,
Asst.Prof. of CBMG
& I/c HoD of CBMG,
SDUAHER.
2. The concerned students,
B.Sc. Women's College, Kolar.

Copy to:

1. PA to VC, SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The Finance Officer, SDUAHER.
4. O/c.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/706/2024-25

Date: 25-05-2024

NOTE

Sub: Permission to start internship for B.Sc. Women's College students of Kolar-reg.

Ref. Letter No: SDUAHER/KLR/CBMG/128/2024-25 dated 21-05-2024 from Dr. Kiranmayee.P, Asst.Prof. of CBMG & I/c HoD of CBMG, SDUAHER.

With reference to above letter, permission has been granted by the Academy to undergo Internship in Dept. of CBMG under FAH&BS, SDUAHER from B.Sc. Women's College students of Kolar for 90 hours (6 Biotechnology students). The following students' names are hereunder.

- | | |
|----------------------|--------------------|
| 1. Ms. P.S. Sireesha | 5. Ms. Lavanya C.S |
| 2. Ms. Daniya Kousar | 6. Ms. Afreen Taj |
| 3. Ms. Bhavya B.H | |
| 4. Ms. Dhanyashree S | |

It is intimated that to collect Rs. 2000/- per month from each student to monitor during internship as per internship policy.

This is for your kind information and further needful action.

Rs. 500/- for 7 days of Internship

Registrar

Registrar

Sri Devaraj Urs Academy of Higher
Education and Research
Tamaka, Kolar - 563 103.

To,

1. Dr. Kiranmayee.P,
Asst.Prof. of CBMG
& I/c HoD of CBMG,
SDUAHER.
2. The concerned students,
B.Sc. Women's College, Kolar.

Copy to:

1. PA to VC, SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The Finance Officer, SDUAHER.
4. O/c.



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH

(A Deemed to be University declared under Section 3 of UGC Act 1956)

Comprising Sri Devaraj Urs Medical College

[Constituent unit of Sri Devaraj Urs Educational Trust for Backward Classes (Regd.)]

TAMAKA, KOLAR-563 103, KARNATAKA, INDIA

Ph: 918152-243003, +91 9448395232, E-mail - registrar@sduaher.ac.in / office@sduaher.ac.in. Website: www.sduaher.ac.in

No. SDUAHER/KLR/ADMIN/706/2024-25

Date: 25-05-2024

NOTE

Sub: Permission to start internship for B.Sc. Women's College students of Kolar-reg.

Ref.Letter No: SDUAHER/KLR/CBMG/128/2024-25 dated 21-05-2024 from Dr. Kiranmayee.P, Asst.Prof. of CBMG & I/c HoD of CBMG, SDUAHER.

With reference to above letter, permission has been granted by the Academy to undergo Internship in Dept. of CBMG under FAH&BS, SDUAHER from B.Sc. Women's College students of Kolar for 90 hours (6 Biotechnology students). The following students' names are hereunder.

- | | |
|----------------------|--------------------|
| 1. Ms. P.S. Sireesha | 5. Ms. Lavanya C.S |
| 2. Ms. Daniya Kousar | 6. Ms. Afreen Taj |
| 3. Ms. Bhavya B.H | |
| 4. Ms. Dhanyashree S | |

It is intimated that to collect Rs. 2000/- per month from each student to monitor during internship as per internship policy.

This is for your kind information and further needful action.

Rs. 500/- for 7 days of internship


Registrar

To,

1. Dr. Kiranmayee.P,
Asst.Prof. of CBMG
& I/c HoD of CBMG,
SDUAHER.
2. The concerned students,
B.Sc. Women's College, Kolar.

Copy to:

1. PA to VC, SDUAHER.
2. The Dean, FAH&BS, SDUAHER.
3. The Finance Officer, SDUAHER.
4. O/c.

Registrar
Sri Devaraj Urs Academy of Higher
Education and Research
Tumaka, Kolar - 563 103.



Sri Devaraj Urs Academy Of Higher Education & Research

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0001194	Date :	31/05/2024
Name :	LAVANYA C S (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	500.00	
Total Amount Paid :		500.00	
Amount In Words :	FIVE HUNDRED ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	Cash	Date/Time :	
Bank	N/A		
Branch	N/A	DD No.	

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Kolar - 563 103.

**Sri Devaraj Urs Academy Of Higher Education & Research**

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0001196	Date :	31/05/2024
Name :	P S SIREESHA (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	500.00	
Total Amount Paid :		500.00	
Amount In Words :	FIVE HUNDRED ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	31/05/2024
Bank	State Bank of India		
Branch	Sdumc 2124	DD No.	415230518519

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.

**Sri Devaraj Urs Academy Of Higher Education & Research**

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0001198	Date :	31/05/2024
Name :	DHANYASHREE S (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	500.00	
Total Amount Paid :		500.00	
Amount In Words :	FIVE HUNDRED ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	31/05/2024
Bank	State Bank of India		
Branch	Sdumc 2124	DD No.	415230518519

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.

**Sri Devaraj Urs Academy Of Higher Education & Research**

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0001193	Date :	31/05/2024
Name :	BHAVYA B H (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	500.00	
Total Amount Paid :		500.00	
Amount In Words :	FIVE HUNDRED ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	Cash	DateTime :	
Bank	N/A		
Branch	N/A	DD No.	

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.

**Sri Devaraj Urs Academy Of Higher Education & Research**

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-563101

Receipt

Receipt No :	2024-25/MF/0001197	Date :	31/05/2024
Name :	DANIYA KOUSAR (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	500.00	
Total Amount Paid :		500.00	
Amount In Words :	FIVE HUNDRED ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	31/05/2024
Bank	State Bank of India		
Branch	Sdumc 2124	DD No.	415230518519

This receipt is electronically generated and does not require a signature


Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.

**Sri Devaraj Urs Academy Of Higher Education & Research**

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka, India-563101

Receipt

Receipt No :	2024-25/MF/0001195	Date :	31/05/2024
Name :	AFREEN TAJ (B.SC)	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	500.00	
Total Amount Paid :		500.00	
Amount In Words :	FIVE HUNDRED ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	Cash	DateTime :	
Bank	N/A		
Branch	N/A	DD No.	

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Kolar - 563 103.

Department of CBMG
Revenue Generated from department (June-2025 to May-2025)

Sl N	Name of the Student	Course	College Name
1	Lavanya C S	B.Sc. Biotechnology	Womens college,Kolar
2	P S Sireesha	B.Sc. Biotechnology	Womens college,Kolar
3	Dhanyashree S	B.Sc. Biotechnology	Womens college,Kolar
4	Bhavya B H	B.Sc. Biotechnology	Womens college,Kolar
5	Dantya Kousar	B.Sc. Biotechnology	Womens college,Kolar
6	Afreen Taj	B.Sc. Biotechnology	Womens college,Kolar
7	Sandhya	B.Sc. Biotechnology	Maharani Cluster University Banglore
8	Haritha	B.Sc. Biotechnology	Maharani Cluster University Banglore
9	Deepthi	B.Sc. Biotechnology	Maharani Cluster University Banglore
10	Deepthi, R.	B.Sc. Biotechnology	Sri Bahawan Mahaveer Jain College,KGF
11	Vidhyasree R C,	B.Sc. Biotechnology	Sri Bahawan Mahaveer Jain College,KGF
12	Griselda P	B.Sc. Biotechnology	Sri Bahawan Mahaveer Jain College,KGF
13	Irinda J	B.Sc. Biotechnology	Sri Bahawan Mahaveer Jain College,KGF
14	Blessy Mayor Maneksha C	B.Sc. Biotechnology	Sri Bahawan Mahaveer Jain College,KGF
15	Keerthana S K	BE in Biotechnology	Sir M Visevesvaraya Institute of Technology
16	Pavana	M.tech Student	JSS Sceince and Technology University,Mys
17	Pavana	M.tech Student	JSS Sceince and Technology University,Mys
18	Dr.Satydeo Kumar Sing	PG Biochem	SDUMC
19	Ramagiri Sateesh	Ph.D Biochem	SDUMC
20	Bhavana Taj	B.Sc. Biotechnology	Womens college,Kolar
21	Fareen Taj	B.Sc. Biotechnology	Womens college,Kolar
22	Chitra Bai M	B.Sc. Biotechnology	Womens college,Kolar
23	Akshitha R	B.Sc. Biotechnology	Womens college,Kolar
24	Sarika T.N	B.Sc. Biotechnology	Womens college,Kolar
25	Arpitha.M	B.Sc. Biotechnology	Womens college,Kolar
26	Surya H.M	B.Sc. Biotechnology	Womens college,Kolar
27	Keerthana V.R	B.Sc. Biotechnology	Womens college,Kolar
28	Chandana.N	B.Sc. Biotechnology	Womens college,Kolar



Sri Devaraj Urs Academy of Higher Education and Research

(A Deemed to be University)

Research and Development Cell (R&D)

&

Intellectual Property Rights Cell (IPR)

Tamaka, Kolar. Karnataka. - 563103



No. SDUAHER/KLR/IPR Cell/05 /2025-26

Date: 12/05/2025

To,
The Registrar,
SDUAHER,
Tamaka, Kolar- 563103.

Respected Sir,

Subject: Submission of the expenditure of One day CME on World Intellectual Property Rights Day 2025.

With respect to the above subject please find the expenditure towards One day CME on World Intellectual Property Rights Day 2025. Details of the expenditure are mentioned in the table below and bills attached for your kind perusal. Please note the amount sanctioned by the academy is Rs 50,000/-, approved financial assistance from MERT is Rs 10,000/- and the conference registration amount by delegates and participants is Rs 19,400/- [Total = Rs. 79,400]. The total expenditure is Rs 51802/- and balance is Rs. 27598/-

The account details of the resources persons are enclosed and the dues have to be paid to Mr. R. Bharath [Emp code: C3020]. Please do the needful.

Thanking You


Dr. Sangeetha. T

Chief coordinating officer

IPR Cell, SDUAHER
Chief Co-ordinating Officer
Intellectual Property Rights (IPR)
Research and Development Cell, SDUAHER


Dr. Kalyani R

Director

R&D Cell, SDUAHER
Prof. Dr. Kalyani . R.
MD(Path), Ph.D, FAMS, FICP, FIAMS, FIMSA, FKSTA
Director
Research and Development Cell, SDUAHER
Professor & Former Head
Dept. of Pathology, SDUMC





MEDICAL EDUCATION & RESEARCH TRUST (R)

KARNATAKA

API BHAVANA, # 16/F, Millers Tank Bund Road, Vasanthanagar, Bengaluru - 560 052.
Ph: 2235 3525 / 4149 4070, E-mail : info@mert.org.in, Website: www.mert.org.in

Founder Chairman :
Late Dr. K.S. Shadaksharappa

Emeritus Chairman :
Dr. M. Maiya
☎ : 2660 7447 (R), 98450 41731

Chairman :
Dr. P. Chandrasekhara
Mo.: 95356 78965

Vice Chairman :
Dr. S. T. Yavagal
Mo.: 98450 05350

Hon. Secretary :
Dr. V. Channaraya
Mo.: 93412 34049

Hon. Joint Secretary :
Dr. Latha Venkataraman
Mo.: 98450 34547

Hon. Treasurer :
Dr. K. Ravi
Mo.: 98451 28212

Trustee's
Dr. M. Maiya
Dr. C. Munichoodappa
Dr. S.T. Yavagal
Dr. T. Prabhu
Dr. P. Mohan Rao
Dr. I.B. Vijayalakshmi
Dr. A.C. Sreeram
Dr. P. Chandrasekhara
Dr. V. Channaraya
Dr. S. M. Sureswaraiah
Dr. K. S. S. Bhat
Dr. K. Ravi
Dr. Latha Venkataraman
Dr. Asha Benakappa

Rotating Trustees :
Dr. M. Narayanaswamy (2026)
Dr. B. S. Nagaraja (2025)
Dr. B. J. Subhash Chandra (2025)
Dr. Shubha Badami (2025)

Institutional Trustees :
API Chairman
IMA President

2025-2026
Ref. No.:

Date : 19.04.2025

Dr.Muninarayan C
Registrar
Dept of Research &
Development Cell (R & D)
SDUAHER
Tamaka, Kolar


Dear Dr.Muninarayan.C

Thank you for your letter dt: 08.04.2025 along Programme for Financial Assistance to conduct CME on "**World Intellectual Property Rights day**". We are glad to Sanction Rs.10,000/- (Rupees Ten thousand Only) towards your CME. It is Necessary that the name and Logo of "**MEDICAL EDUCATION & RESEARCH TRUST**" KARNATAKA should be mentioned in your Program as sponsorer. I request you to Send the Program brochure and Photos. We will be Releasing the said amount after receiving your program report. In the covering letter please mention the cheque Pay name.

Thanking you,

Yours sincerely,

(Dr.P.Chandrasekhara)
Chairman


(Dr.V.Channaraya)
Hon.Secretary



Sri Devaraj Urs Academy of Higher Education & Research
A DEEMED TO BE UNIVERSITY

Dept. of Clinical Nutrition and Dietetics (CND)

Declared under Section 3 of UGC Act, 1956, MHRD GOI No.F.9-36/2006-U.3(A) Dt. 25th May 2007

POST BOX NO.62, TAMAKA, KOLAR-563 101, KARNATAKA, INDIA

Ph: 08152-243003, 210604, 210605, Fax: 08152-243008, E-mail: : nutrition@sduaher.ac.in Website: www.sduaher.ac.in

No. SDUAHER/KLR/CND/ 43 / 2025-26

Date: 10.05.2025

To
The Research & Development cell
SDUAHER,
Tamaka, Kolar

Respected Sir/Madam,

Subject: Revenue generated from external students internship from June 2024 to May 2025– reg.

As per your mail I am hereby submitting the List of Students Internship details between June 2024 to May 2025. The details are given below.

Sl No	Name	Program	Register No	Student exchange / Internship	Revenue Rs/-
1.	Ms. Vinutha N A	Clinical Nutrition and Dietetics	P20AU22S050013	Internship	2000.00
2.	Ms. Hemavarna T V	Clinical Nutrition and Dietetics	P20AU22S050015	Internship	2000.00

Thanking You

Yours Sincerely,

Dr. Shivakumara. C.S

Assistant Professor & I/c HOD

Prof. & HOD
Department of
Clinical Nutrition and Dietetics
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar-563101

**Sri Devaraj Urs Academy Of Higher Education & Research**

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-583101

Receipt

Receipt No :	2024-25/MF/0001361	Date :	07/06/2024
Name :	VINUTHA N A ()	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	2,000.00	
Total Amount Paid :		2,000.00	
Amount In Words :	TWO THOUSAND ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	07/06/2024
Bank	State Bank of India		
Branch	Sdumc 2124	DD No.	415983796686

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.

**Sri Devaraj Urs Academy Of Higher Education & Research**

DEEMED UNIVERSITY

Established Under Section 3 of UGC Act, 1956 MHRD GOI No.9-36/2006-U.3(A) Dt. 25th May 2007

Sri Devaraj Urs Medical College

Tamaka , Kolar, Karnataka. India-583101

Receipt

Receipt No :	2024-25/MF/0001362	Date :	07/06/2024
Name :	HEMAVARNA T V ()	Roll No :	N/A
Program :	OTH	Year :	2024-25
Semester/Standard:	N/A	Division :	
No.	Particulars	Amount	
1	Miscellaneous Fees-INTERNSHIP FEE	2,000.00	
Total Amount Paid :		2,000.00	
Amount In Words :	TWO THOUSAND ONLY		
Additional Comment			
Details of Payment			
Payment Mode :	NEFT	DateTime :	07/06/2024
Bank	ICICI Bank		
Branch	Sdumc 2124	DD No.	452562335947

This receipt is electronically generated and does not require a signature

Cashier
Sri Devaraj Urs Academy of
Higher Education and Research
Tamaka, Kolar - 563 103.



Sri Devaraj Urs College of Nursing

(A unit of Sri Devaraj Urs Educational Trust)

Tamaka, Kolar-563103, Karnataka.

(Affiliated to RGUHS, Bangalore and Recognized by KNC, Bangalore & INC, New Delhi)

Phone: 9480880802

ISO 9001: 2015 Certified & NAAC Accredited

E-mail: sducunsona@yahoo.com

Website: sducon.ac.in

Ref.No SDUCON/ 2024-25

Dates:24-06-2024

To
The Vice Chairman,
SDUET,
Tamaka, Kolar-563103.

Sir,
Sub.: Requesting to release amount spent for Research methodology workshop - reg.

With subject to the above, Here by I am submitting the following expenditure made towards Research Methodology Workshop, which was held on 19th and 20th June 2024. Further I request you to release Rs.51,641/- to Vendors/Principal/ through NEFT/RTGS and do the needful.

Sl. No.	Particulars	Amount (Rs.)	Remarks
1	Paid Modern Family shop, Tax Invoice No.8360/Dt.18-06-2024 of, towards Gift purchased for resource person	2,415/-	Paid to Mrs.Malathi K.V., Asso.Prof.SDUCON
2	Paid to Ashraya Hospitality, Tax Invoice No.81/Dt.19/06/2024 Services, towards purchase snacks .	2,130/-	To be paid to Vendors as per enclosed details
3	Paid to SDUMC consumer Co-op. Society, Tax Invoice No.862/861,Dt 20/06/2022 towards purchase snacks and stationery	4,776/-	
4	Paid to Harish printers, Bill No.161/Dt.20/06/2024 towards certificates print	4,125/-	
5	Paid to Sai Ram Enterprises, Bill No. dt.20/06/2024	3,435/-	
6	Paid to Shree Sudha Steel, Tax Invoice No.198/19/06/2024, towards purchase momentos	30,000/-	Principal SDUCON
7	Paid to Keerthi Farm and Nursery, Tax Invoice No.780&745,Dt.20/06/2024 and 22/06/202, towards purchase Pots and plants	2,500/-	
8	Bill no. Nil/Dt.19/06/2024, towards purchase stationery	260/-	Release Each one Rs.500/- Mr.Rajendra Prasad, Lecturer, SDUCON Mrs.Sumalatha, Asst.. prof., SDUCON Mrs.Uma V., Lecturer, SDUCON. Ms.Gethcia ., Lecturer , SDUCON.
9	Concession to faculty for paper presentation	2,000/-	
10	Food and snack charges of SDUCONH Food - 155 members XRs.50/-X02 days - Rs.15,500/- Snacks -155 membersXRs.10/-X02 days - Rs.3,100/- Tea-265 membersXRs.10/-X02 times - Rs.5,300/- Tea-155 membersXRs.10/-X02 times - Rs.3,100/-	27,000/-	Kept in College Account towards SDUCON Hostel Expenditure
Total		78,641/-	

(Rupees seventy eight thousand six hundred forty one only)

Total Amount Collected - Rs.78,200-00

Total Expenditure - Rs.78,641-00

Deficit Rs.441/-

Thanking you,

Yours faithfully,

*Forwarded to RO.
SDUET & request to
release the same*

Principal

Principal

Encl.: 1. Copy of permission letter
2. Original Tax Invoice

Sri Devaraj Urs College of Nursing
Tamaka, Kolar-563103



Sri Devaraj Urs College of Nursing
A Constituent unit of Sri Devaraj Urs Academy of Higher Education and Research
(Deemed to be University)
(Recognized by KNC, Bangalore & INC, New Delhi)
ISO 9001: 2015 Certified & NAAC Accredited
Tumaka, Kolar-563 103, Karnataka.
Phone: 9480880802 E-mail: sduconson@yahoo.com Website: sducon.ac.in



Ref.No.SDUCON/120/2024-25

Date:24-06-2024

Research Methodology Workshop 19th and 20th June 2024

Income

Sl. No.	Particulars	Course	No.of students	Amount (Rs.)	Total Amount (Rs.)
1	SDUCON	B.Sc.(N)- Hostel	79	100/-	7,900/-
		Day scholars	18	200/-	3,600/-
		M.Sc.(N)	09	300/-	2,700/-
2	SDUCON	Faculty	05	500/-	2,500/-
3	Shanthi CON		54	500/-	27,000/-
4	Eshwarammaji CON		14	500/-	7,000/-
5	SLES CON		55	500/-	27,500/-
Total Income					78,200/-

Expenditure

Sl. No.	Particulars	Total Amount (Rs.)
1	Food and Snacks	29130/-
2	Certificates	4,125/-
3	Honorarium, Mementoes (Including chief guest) & Prizes	32,415/-
4	Stationery, Chart Lamination	8,471/-
5	Concession to faculty for paper presentation	2,000/-
6	Miscellaneous	2,500/-
Total Expenditure		78,641/-


Principal
24/06/24

Sri Devaraj Urs College of Nursing
Tumaka, Kolar-563103

From,

Research and Development Cell
SDUCON, Tamaka, Kolar

To:

The Principal,
SDUCON,
Tamaka, Kolar.

Sub: Requesting to sanction and conduct Research
Methodology Workshop at Regional level Reg:

Respected madam,

With the subject mentioned above from Department of Research and Development Cell SDUCON placing a kind request to release and grant permission to conduct Research Methodology Workshop at Regional for UG and PG students on 19-06-24 to 20-06-24. Here by enclosing the proposed budget plan for the same. Kindly grant permission and do the needful.

Thanking you,

Place: Tamaka, Kolar

Date: 3-06-24

Yours faithfully,

ML Subashini
Dr. Lavanya Subashini,

Submitted to Vice chairman, SDUET
to a request to grant permission
to conduct workshop on above mentioned
dates
[Signature]
05/06/24

Proved
[Signature]



ರಾಜೀವ್ ಗಾಂಧಿ ಆರೋಗ್ಯ ವಿಜ್ಞಾನಗಳ ವಿಶ್ವವಿದ್ಯಾಲಯ, ಕರ್ನಾಟಕ

Rajiv Gandhi University of Health Sciences, Karnataka

4th T Block, Jayanagar, Bengaluru - 560041

ರಾಷ್ಟ್ರೀಯ ಸೇವಾ ಯೋಜನೆ
National Service Scheme



Ref. No.: RGU/NSS/Grants/R&S/05/2024-25

Date: 05.03.2025

To,

The Principals of colleges,
having NSS Units affiliated to RGUHS.

Respected Sir/Madam,

Sub: Submission of NSS Annual Activities Report & Accounts for NSS Grants released for the year 2024-25 – reg.

Ref.:1. University NSS Letter No.: RGUHS/NSS/R.S.G.-2024-25/01/2024-25 dated 08.07.2024.

2. University NSS Letter No.: RGUHS/NSS/R.S.G.-2024-25/02/2024-25 dated 29.07.2024.

With reference to the subject cited, I am to inform you that RGUHS NSS Cell have been released **NSS Grants of Rs.71,000/- (Regular Activities - Rs.36,000/- & Special Camping Grants - Rs.35,000/-) for the year 2024-25** to the colleges through PFMS.

In this connection, you are here by requested to direct the concerned NSS Program Officer to submit the NSS Annual Activities Report and Accounts (for both Regular & Special Camping Activities) along with Original Bills for NSS Grants sanctioned for the year 2024-25 should be **submitted to this office by 25th March 2025** for onward submission to Govt. of India.

A Break up of NSS Grants and guidelines for proper submission of Report & Bills is enclosed for submission of Accounts as per the expenditure heads.

Thanking you,

With regards,

B. Vasanth
Dr. B. Vasantha Shetty,
Deputy Registrar,
NSS Prog. Coordinator,
RGUHS, Bangalore.

Copy to:

1. All the NSS Program Officer of the colleges – for kind information and necessary action.



NSS Grants (Regular Activities & Special Camping Prog.) for the year 2024-25

Expenditure Details for NSS Regular Activities Grants as per GOI Guidelines

Allocation of NSS Regular fund per College Rs.36,000/- per year.

Following are the details of amount sanctioned to each head.

Sl. No.	Particulars	Amount Sanctioned per year (in Rs.)
1	a. To organize NSS Regular activities in the colleges. b. Pre-camp preparation, pre-camp orientation, post-camp evaluation. c. Expenses on TA and honorarium to resource persons. d. Refreshment to students. e. Travel expenses of students from institutions to the place of work and back by the cheapest mode of transportation. f. Purchase of utensils, equipment, etc. required for camps and regular programmes. g. Travel expenses in respect of Programme Officers for participation in meetings, seminars, orientation and refresher courses, camps etc. h. Travel expenses (by cheapest mode) in respect of NSS volunteers for participation in camps, meetings, seminars, conferences etc.	27,500.00
2	Contingency Expenditure like purchase of Stationary, Postage, Part time Clerical/Data Entry Assistance & other miscellaneous expenses.	02,500.00
	Total (Regular Activities)	30,000.00
3	Out of Pocket Allowance for NSS Programme Officers	06,000.00
	Grand Total	36,000.00

Expenditure Details for NSS Special Camping Grants as per GOI Guidelines

Allocation of Special Camping fund per College Rs.35,000/- per year.

A grant per NSS Volunteer Rs. 700/- for 7 days (700X50 Volunteers)

Sl. No.	Particulars	Amount Sanctioned per year (in Rs.)
1	Expenditure on board & lodging (Refreshment to Students) Pre-camp Preparation, Pre-camp Orientation, Post-camp Evaluation Transportation & Miscellaneous.	35,000.00
	Total	35,000.00

Note: The Programme Development expenditure can be spent by proper bills or through vouchers/receipts of the college signed by NSS Programme Officer, Principal of the concerned institution and submit original bills to the University NSS Section.

B. Ashwaj
08/07/24
NSS Programme Co-ordinator,
National Service Scheme
RGUHS, Bangalore



ರಾಜೀವ್ ಗಾಂಧಿ ಆರೋಗ್ಯ ವಿಜ್ಞಾನಗಳ ವಿಶ್ವವಿದ್ಯಾಲಯ, ಕರ್ನಾಟಕ

Rajiv Gandhi University of Health Sciences, Karnataka

ರಾಷ್ಟ್ರೀಯ ಸೇವಾ ಯೋಜನೆ
National Service Scheme



Guidelines/Procedure for

Proper Submission of NSS Activities Report & Bills

NSS Regular Activities & Special Camping Programme:-

Do's:

1. Allocated funds (Regular & Special) should be utilized as per the head wise only.
 2. Separate **Activities Report** should be made for both **Regular Activities & Special Camping** programmes.
 3. **List of Regular Activities** organized by the college should be submitted.
 4. For **Regular Activities** a **List of Participants** for each activity should be submitted.
 5. **Day wise report** with **List of Participants** should be made for **Special Camping Programme**.
 6. A Statement for all Bills should be submitted:-
 - a. Sl. No.
 - b. Date & Name of the Activity
 - c. Particulars (Purpose of Expenditure)
 - d. Amount incurred
 - e. Original Bills should be enclosed*
- * **Note: All Bills should be pasted in a sheet, Signed by the Principal & NSS PO.**
7. Company/Firm GST Bills should be submitted.
 8. Colleges before purchasing Instruments for NSS an approval should be taken from the University NSS Cell.
 9. College Voucher should be submitted for **Claiming of Honorarium** to any resource person.
 10. For any expenditure above **Rs.10,000/-** to any person/Firm/Company should be made with **03 different Quotations** with **Comparative Statement, Supply order** for the concerned & to be submitted along with the bills.
 11. Expenditures on Travelling like **Fuel Expenses** for **College Vehicles** should be submitted with **Log Book Copy** of the vehicle.
 12. For Purchasing of **Medicines for Health Check-up Camp**, A Beneficiaries list should be submitted with the activity report.

Don'ts

1. Xerox Bills is not acceptable.
2. Phone Pay/Google Pay Bills is not acceptable.
3. College Vouchers for any other bills are not acceptable.
4. Paper receipt is not acceptable.
5. Colleges paying donation to private organization from NSS Funds is not permissible.

B. Vishwas
08-07-24
NSS Programme Co-ordinator,
National Service Scheme
RGUHS, Bangalore

S.D.U.SCHOOL/COLLEGE OF NURSING
NAGARAJ G H

SRI DEVARAJ URS MEDICAL
COLLEGE
TAMAKA
KOLAR-563101
KARNATAKA,INDIA

Period : 01-08-2024 To 31-08-2024
Cust.Rein.No : 2281911
Account No : 182110005542
Currency : INR
Branch : SRI DEVARAJ URS MED COLLEGE
Nominee Registered : N

Branch Address : SRI DEVARAJ URS MEDICAL COLLEGE,

KOLAR-563101
KARNATAKA,INDIA

Branch Phone No. : 7259692627
MICR Code : 563485103
IFSC Code : KKBK0008269

Date	Narration	Chq/Ref No	Withdrawal (Dr)	Deposit(Cr)	Balance
07-08-2024	Sent NEFT KKBKH24220957148/DR VIJAYALAKSHMI.G	000411207342	2,510.00		14,913,579.83(Cr)
07-08-2024	Sent NEFT KKBKH24220958084/KEERTHI FARM NURS	000411208367	15,160.00		14,898,419.83(Cr)
08-08-2024	KOTAKPAYOUT-0798269A0000001-080824	FOS2422133603553		50,000.00	14,948,419.83(Cr)
08-08-2024	NACH-GEN-CR-NSSGRANTS 2024-C082408186275	NACHDB08082400390619		71,000.00	15,019,419.83(Cr)
08-08-2024	NEFT AXISP00526465347 COEMPT EDU TECK PRIVATE LIM	NEFTINW-0934856796		5,280.00	15,024,699.83(Cr)
09-08-2024	KOTAKPAYOUT-0798269A0000001-090824	FOS2422233824713		1,000.00	15,025,699.83(Cr)
10-08-2024	KOTAKPAYOUT-0798269A0000001-100824	FOS2422333984311		8,698.00	15,034,397.83(Cr)
11-08-2024	KOTAKPAYOUT-0798269A0000001-110824	FOS2422434133623		2,500.00	15,036,897.83(Cr)
12-08-2024	KOTAKPAYOUT-0798269A0000001-120824	FOS2422534271512		25,650.00	15,062,547.83(Cr)
12-08-2024	BY CLG INST 187707/22-07-24/CUB/KOLAR			151,075.00	15,213,622.83(Cr)
12-08-2024	UPI/KISHEN BALU/422567162753/UPI	UPI-422561107872		25,000.00	15,238,622.83(Cr)
12-08-2024	CASH DEPOSIT BY SELF AT SRI DEVARAJ URS MEDICAL			10,000.00	15,248,622.83(Cr)
12-08-2024	NEFT FDRLM8225009907 ANSHAD M FDRL0000037	NEFTINW-0938548899		50,000.00	15,298,622.83(Cr)
12-08-2024	NEFT FDRLM8225015742 ANSHAD M FDRL0000037	NEFTINW-0938575077		50,000.00	15,348,622.83(Cr)
13-08-2024	Sent NEFT KKBKH24226992417/KEDAR GAS AGENCY/C	2362/000412425499	69,440.00		15,279,182.83(Cr)